PT92758A - Metodo para conceber uma cadeia de imunoglobulina humanizada - Google Patents

Metodo para conceber uma cadeia de imunoglobulina humanizada

Info

Publication number: PT92758A
Authority: PT; Portugal
Prior art keywords: human; cdr; receptor; tac; nucleic acid
Prior art date: 1988-12-28

Application number

PT92758A

Other languages

English (en)

Other versions

PT92758B (pt

Inventor

Cary L Queen

Harold E Selick

Original Assignee

Protein Design Labs Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-28

Filing date

1989-12-28

Publication date

1990-06-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26966505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT92758(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1989-12-28 Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc

1990-06-29 Publication of PT92758A publication Critical patent/PT92758A/pt

1996-01-31 Publication of PT92758B publication Critical patent/PT92758B/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PT92758A 1988-12-28 1989-12-28 Metodo para conceber uma cadeia de imunoglobulina humanizada PT92758B (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29097588A	1988-12-28	1988-12-28
US31025289A	1989-02-13	1989-02-13

Publications (2)

Publication Number	Publication Date
PT92758A true PT92758A (pt)	1990-06-29
PT92758B PT92758B (pt)	1996-01-31

Family

ID=26966505

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT92758A PT92758B (pt)	1988-12-28	1989-12-28	Metodo para conceber uma cadeia de imunoglobulina humanizada

Country Status (31)

Country	Link
EP (6)	EP0939127B1 (pt)
JP (6)	JP2828340B2 (pt)
KR (1)	KR0178385B1 (pt)
CN (1)	CN1057013C (pt)
AT (2)	ATE183753T1 (pt)
AU (1)	AU647383B2 (pt)
BG (1)	BG61095B2 (pt)
CA (2)	CA2328851C (pt)
CZ (1)	CZ418691A3 (pt)
DD (1)	DD296964A5 (pt)
DE (14)	DE122005000057I2 (pt)
DK (2)	DK119191D0 (pt)
ES (5)	ES2523810T3 (pt)
FI (1)	FI108797B (pt)
FR (1)	FR14C0070I1 (pt)
HR (1)	HRP920500B1 (pt)
HU (1)	HU211174A9 (pt)
IE (1)	IE20000331A1 (pt)
IL (2)	IL162181A (pt)
LU (8)	LU90411I2 (pt)
MC (1)	MC2146A1 (pt)
NL (8)	NL990020I2 (pt)
NO (9)	NO310473B1 (pt)
NZ (2)	NZ314793A (pt)
PT (1)	PT92758B (pt)
RU (1)	RU2126046C1 (pt)
SG (1)	SG78258A1 (pt)
SI (1)	SI8912489B (pt)
WO (1)	WO1990007861A1 (pt)
YU (1)	YU48700B (pt)
ZA (1)	ZA899956B (pt)

Families Citing this family (1041)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5800815A (en) *	1903-05-05	1998-09-01	Cytel Corporation	Antibodies to P-selectin and their uses
US5851526A (en) *	1985-04-19	1998-12-22	Ludwig Institute For Cancer Research	Methods of treating colon cancer utilizing tumor-specific antibodies
US5449760A (en) *	1987-12-31	1995-09-12	Tanox Biosystems, Inc.	Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US7247453B1 (en) *	1988-12-30	2007-07-24	Oklahoma Medical Research Foundation	Calcium binding recombinant antibody against protein C
DE3900534A1 (de) *	1989-01-10	1990-07-12	Boehringer Mannheim Gmbh	Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
JP3443119B2 (ja)	1989-08-07	2003-09-02	ペプテックリミテッド	腫瘍壊死因子結合リガンド
US20030225254A1 (en)	1989-08-07	2003-12-04	Rathjen Deborah Ann	Tumour necrosis factor binding ligands
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB8928874D0 (en) *	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US6750325B1 (en)	1989-12-21	2004-06-15	Celltech R&D Limited	CD3 specific recombinant antibody
GR1001050B (el) *	1990-01-09	1993-04-28	Protein Design Labs Inc	Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων.
HUT60768A (en)	1990-03-16	1992-10-28	Sandoz Ag	Process for producing cd25 fixing molecules
GB9020282D0 (en)	1990-09-17	1990-10-31	Gorman Scott D	Altered antibodies and their preparation
US5858725A (en) *	1990-10-10	1999-01-12	Glaxo Wellcome Inc.	Preparation of chimaeric antibodies using the recombinant PCR strategy
US5994510A (en) *	1990-12-21	1999-11-30	Celltech Therapeutics Limited	Recombinant antibodies specific for TNFα
DK0531472T3 (da) *	1991-03-06	2003-12-01	Merck Patent Gmbh	Humaniserede monoklonale antistoffer
IL101147A (en) *	1991-03-07	2004-06-20	Gen Hospital Corp	Redirection of cellular immunity by receptor chimeras
ATE169031T1 (de) *	1991-04-05	1998-08-15	Univ Washington	Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
US5795965A (en) *	1991-04-25	1998-08-18	Chugai Seiyaku Kabushiki Kaisha	Reshaped human to human interleukin-6 receptor
DE69233482T2 (de) *	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
WO1994004679A1 (en) *	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
GB9115010D0 (en) *	1991-07-11	1991-08-28	Wellcome Found	Antibody
GB9115364D0 (en)	1991-07-16	1991-08-28	Wellcome Found	Antibody
US5709860A (en) *	1991-07-25	1998-01-20	Idec Pharmaceuticals Corporation	Induction of cytotoxic T-lymphocyte responses
MX9204374A (es) *	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
US6136310A (en)	1991-07-25	2000-10-24	Idec Pharmaceuticals Corporation	Recombinant anti-CD4 antibodies for human therapy
DE69225710T3 (de) *	1991-07-25	2004-10-14	Idec Pharmaceuticals Corp., San Diego	Anregung von antworten zytotoxischer t-lymphozyten
US5756096A (en) *	1991-07-25	1998-05-26	Idec Pharmaceuticals Corporation	Recombinant antibodies for human therapy
US6699472B2 (en)	1991-08-14	2004-03-02	Genentech, Inc.	Method of treating allergic disorders
US6329509B1 (en) *	1991-08-14	2001-12-11	Genentech, Inc.	Anti-IgE antibodies
ATE188708T1 (de) *	1991-08-21	2000-01-15	Novartis Ag	Antikörperderivate
GB9120467D0 (en) *	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
JP3024311B2 (ja) *	1991-10-03	2000-03-21	味の素株式会社	Ｉｌ−２受容体重鎖に結合するポリペプチド
US7070777B1 (en)	1991-11-15	2006-07-04	The Trustees Of Columbia University In The City Of New York	Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) *	1991-11-15	1995-12-12	The Trustees Of Columbia University In The City Of New York	Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5817310A (en)	1991-12-02	1998-10-06	Cor Therapeutics, Inc.	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
JPH05244982A (ja) *	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
DE69233204T2 (de) *	1991-12-13	2004-07-15	Xoma Corp., Berkeley	Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5869619A (en) *	1991-12-13	1999-02-09	Xoma Corporation	Modified antibody variable domains
US5777085A (en) *	1991-12-20	1998-07-07	Protein Design Labs, Inc.	Humanized antibodies reactive with GPIIB/IIIA
US5824307A (en)	1991-12-23	1998-10-20	Medimmune, Inc.	Human-murine chimeric antibodies against respiratory syncytial virus
ATE419355T1 (de) *	1992-02-06	2009-01-15	Novartis Vaccines & Diagnostic	Marker für krebs und biosynthetisches bindeprotein dafür
GB9203459D0 (en) *	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5387676A (en) *	1992-03-11	1995-02-07	Ciba Corning Diagnostics Corp.	MN gene and protein
US6129914A (en) *	1992-03-27	2000-10-10	Protein Design Labs, Inc.	Bispecific antibody effective to treat B-cell lymphoma and cell line
US7381803B1 (en)	1992-03-27	2008-06-03	Pdl Biopharma, Inc.	Humanized antibodies against CD3
US6033667A (en) *	1992-05-05	2000-03-07	Cytel Corporation	Method for detecting the presence of P-selectin
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
US5874082A (en) *	1992-07-09	1999-02-23	Chiron Corporation	Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5639641A (en) *	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5958708A (en) *	1992-09-25	1999-09-28	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) *	1992-09-25	2000-05-23	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9223377D0 (en) *	1992-11-04	1992-12-23	Medarex Inc	Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5648267A (en) *	1992-11-13	1997-07-15	Idec Pharmaceuticals Corporation	Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en)	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
DE669986T1 (de) *	1992-11-13	1996-10-10	Idec Pharma Corp	Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
ES2091684T3 (es)	1992-11-13	1996-11-01	Idec Pharma Corp	Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5804187A (en) *	1992-11-16	1998-09-08	Cancer Research Fund Of Contra Costa	Modified antibodies with human milk fat globule specificity
DK0678122T3 (da)	1993-01-12	2000-03-06	Biogen Inc	Rekombinante anti-VLA4 antistofmolekyler
US5951983A (en) *	1993-03-05	1999-09-14	Universite Catholique De Louvain	Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5730979A (en) *	1993-03-05	1998-03-24	Universite Catholique Delouvain	LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5817311A (en) *	1993-03-05	1998-10-06	Universite Catholique De Louvain	Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
WO1994025067A1 (en) *	1993-05-04	1994-11-10	Cytel Corporation	Antibodies to p-selectin and their uses
ATE335072T1 (de) *	1993-05-28	2006-08-15	Scripps Research Inst	Methoden für inhibition der cd14-abhängigen zellaktivierung
AU6808194A (en) *	1993-05-31	1994-12-20	Chugai Seiyaku Kabushiki Kaisha	Reconstructed human antibody against human interleukin-6
US6180377B1 (en) *	1993-06-16	2001-01-30	Celltech Therapeutics Limited	Humanized antibodies
RU2162711C2 (ru) *	1993-09-07	2001-02-10	Смитклайн Бичам Корпорейшн	Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US5928904A (en) *	1993-09-07	1999-07-27	Smithkline Beecham Corporation	DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH09502708A (ja) *	1993-09-07	1997-03-18	スミスクライン・ビーチャム・コーポレイション	Ｉｌ４により伝達される疾患の治療に有用な組み換え型ｉｌ４抗体
US20020193575A1 (en)	1993-09-07	2002-12-19	Smithkline Beecham P.L.C.	Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) *	1993-09-07	1999-06-22	Smithkline Beecham Corporation	Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
EP0729976A1 (en)	1993-11-19	1996-09-04	Chugai Seiyaku Kabushiki Kaisha	Reconstituted human antibody against human medulloblastomatous cell
AU2185195A (en) *	1993-11-30	1995-06-19	Protein Design Labs, Inc.	Reperfusion therapy using antibodies to L-selectin
GB9325182D0 (en) *	1993-12-08	1994-02-09	T Cell Sciences Inc	Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US7435802B2 (en)	1994-01-25	2008-10-14	Elan Pharaceuticals, Inc.	Humanized anti-VLA4 immunoglobulins
JP4115517B2 (ja) *	1994-01-25	2008-07-09	エランファーマシューティカルズ，インコーポレイテッド	白血球付着分子ｖｌａ−４に対するヒト化抗体
US5840299A (en) *	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
CA2186455A1 (en)	1994-03-29	1995-10-05	Raymond John Owens	Antibodies against e-selectin
US5635597A (en) *	1994-05-27	1997-06-03	Affymax Technologies, N.V.	Peptides that bind IL-2 receptors
US5622701A (en)	1994-06-14	1997-04-22	Protein Design Labs, Inc.	Cross-reacting monoclonal antibodies specific for E- and P-selectin
USRE39548E1 (en) *	1994-06-17	2007-04-03	Celltech R&D Limited	Interleukin-5 specific recombinant antibodies
GB9412230D0 (en)	1994-06-17	1994-08-10	Celltech Ltd	Interleukin-5 specific recombiant antibodies
US6048972A (en) *	1994-07-13	2000-04-11	Chugai Pharmaceutical Co., Ltd.	Recombinant materials for producing humanized anti-IL-8 antibodies
DE4425115A1 (de) *	1994-07-15	1996-01-18	Boehringer Mannheim Gmbh	Verfahren zur Modifizierung der Stabilität von Antikörpern
EP0696455A1 (en) *	1994-08-11	1996-02-14	Cellena (Cell Engineering) A.G.	Transferrin compositions to alleviate the side effects of cytotoxic drugs
US8771694B2 (en) *	1994-08-12	2014-07-08	Immunomedics, Inc.	Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5707621A (en) *	1994-08-31	1998-01-13	Chugai Pharmaceutical Co., Ltd.	Supression of nephritis-induced protein excretion by anti-IL-8
US6309636B1 (en) *	1995-09-14	2001-10-30	Cancer Research Institute Of Contra Costa	Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5683892A (en) *	1994-12-23	1997-11-04	Smithkline Beecham Corporation	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7175847B1 (en)	1995-06-07	2007-02-13	Biogen Idec Inc.	Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en)	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5811524A (en) *	1995-06-07	1998-09-22	Idec Pharmaceuticals Corporation	Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US7153508B2 (en)	1995-06-07	2006-12-26	Biogen Idec Inc.	Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
AU6171196A (en) *	1995-06-07	1996-12-30	Sloan-Kettering Institute For Cancer Research	Therapeutic uses of ta99
US6001358A (en) *	1995-11-07	1999-12-14	Idec Pharmaceuticals Corporation	Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en)	1995-11-07	2002-08-27	Idec Pharmaceuticals Corporation	Methods of treating autoimmune diseases with gp39-specific antibodies
GB9600660D0 (en)	1996-01-12	1996-03-13	Ciba Geigy Ag	Protein
US6046310A (en) *	1996-03-13	2000-04-04	Protein Design Labs., Inc.	FAS ligand fusion proteins and their uses
US5882644A (en) *	1996-03-22	1999-03-16	Protein Design Labs, Inc.	Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6713305B1 (en)	1996-04-29	2004-03-30	Novartis Ag	Metastasis-associated antigen and antibodies thereto
EP0909277B2 (en)	1996-06-07	2008-12-24	Poniard Pharmaceuticals, Inc.	Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
US6534311B2 (en)	1996-07-24	2003-03-18	Novartis Ag	Drosophila melanogaster p70S6 kinase
US6833255B1 (en)	1996-07-24	2004-12-21	Novartis, Ag	Drosophila melanogaster p70 S6 kinase
US7147851B1 (en)	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
EP1642908A2 (en) *	1996-09-02	2006-04-05	Okumura, Ko	Apoptosis-induced site from fas ligand
US6013256A (en) *	1996-09-24	2000-01-11	Protein Design Labs, Inc.	Method of preventing acute rejection following solid organ transplantation
IL129164A (en)	1996-09-26	2007-05-15	Chugai Pharmaceutical Co Ltd	An antibody against peptides associated with human parathyroid hormone
UA76934C2 (en)	1996-10-04	2006-10-16	Chugai Pharmaceutical Co Ltd	Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US7883872B2 (en)	1996-10-10	2011-02-08	Dyadic International (Usa), Inc.	Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US20020160005A1 (en)	1996-11-15	2002-10-31	Trustees Of Tufts College	Human neutralizing antibodies against hemolytic urmec syndrome
US7910096B2 (en)	1996-11-15	2011-03-22	Trustees Of Tufts College	Human neutralizing antibodies against hemolytic uremic syndrome
WO1998028424A2 (en)	1996-12-23	1998-07-02	Immunex Corporation	Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
US6262238B1 (en) *	1997-01-14	2001-07-17	Roche Diagnostic, Gmbh	Process for modifying the stability of antibodies
US6590079B2 (en)	1997-01-30	2003-07-08	Ixsys, Incorporated	Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6596850B1 (en)	1998-01-30	2003-07-22	Ixsys, Incorporated	Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US20060235209A9 (en)	1997-03-10	2006-10-19	Jin-An Jiao	Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en)	1997-03-10	1999-11-16	Sunol Molecular Corporation	Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en)	2001-11-21	2003-06-12	Sunol Molecular Corporation	Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en)	1997-03-10	2010-07-06	Genentech, Inc.	Antibodies for inhibiting blood coagulation and methods of use thereof
AU736287B2 (en) *	1997-03-21	2001-07-26	Sankyo Company Limited	Humanized anti-human Fas antibody
US6972323B1 (en)	1997-04-01	2005-12-06	Sankyo Company, Limited	Anti-Fas antibodies
US20070059302A1 (en)	1997-04-07	2007-03-15	Genentech, Inc.	Anti-vegf antibodies
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
ES2236634T3 (es)	1997-04-07	2005-07-16	Genentech, Inc.	Anticuerpos anti-vegf.
DE69837707T2 (de)	1997-05-15	2008-01-10	Chugai Seiyaku K.K.	Heilmittel für kachexie
ES2258817T3 (es) *	1997-05-21	2006-09-01	Biovation Limited	Metodo para la produccion de proteinas no inmunogenas.
EP1019082B2 (en)	1997-10-02	2008-06-04	Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V.	Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections
JP3992298B2 (ja)	1997-10-03	2007-10-17	中外製薬株式会社	天然ヒト型化抗体
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
EP1745799B1 (en)	1998-03-04	2015-09-02	The Trustees of The University of Pennsylvania	Compositions and methods of treating tumors
JP3998419B2 (ja)	1998-04-03	2007-10-24	中外製薬株式会社	ヒト組織因子（ｔｆ）に対するヒト型化抗体およびヒト型化抗体の作製方法
JP2002522511A (ja)	1998-08-11	2002-07-23	アイデックファーマスーティカルズコーポレイション	抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
JP4689781B2 (ja) *	1998-09-03	2011-05-25	独立行政法人科学技術振興機構	アミノ酸輸送蛋白及びその遺伝子
DK1113810T3 (da)	1998-09-14	2009-04-06	Univ Texas	Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
AU771539C (en)	1998-10-06	2005-01-13	Dyadic International (Usa), Inc.	Transformation system in the field of filamentous fungal hosts
DE69839740D1 (de)	1998-10-22	2008-08-28	Univ Montana	Vakzine enthaltend Omp85 Proteine von Neisseria gonorrhoeae und Neisseria meningitidis
ES2543819T3 (es)	1998-11-09	2015-08-24	Biogen Inc.	Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
GB9825632D0 (en)	1998-11-23	1999-01-13	Novartis Ag	Organic compounds
US20030035798A1 (en)	2000-08-16	2003-02-20	Fang Fang	Humanized antibodies
IL139321A0 (en)	1999-03-03	2001-11-25	Biogen Inc	Methods and compositions for modulating lipid metabolism
GB9906380D0 (en) *	1999-03-19	1999-05-12	Melvin William T	Monoclonal antibodies specific for cypibi
HK1041452B (en)	1999-04-22	2005-10-14	Biogen Idec Ma Inc.	Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
IT1306704B1 (it) *	1999-05-26	2001-10-02	Sirs Societa Italiana Per La R	Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
CZ300710B6 (cs)	1999-06-01	2009-07-22	Biogen Idec Ma Inc.	Použití blokující monoklonální protilátky proti VLA-1 pro výrobu farmaceutického prípravku k lécení zánetlivých onemocnení
US7144991B2 (en)	1999-06-07	2006-12-05	Aletheon Pharmaceuticals, Inc.	Streptavidin expressed gene fusions and methods of use thereof
US6531580B1 (en)	1999-06-24	2003-03-11	Ixsys, Inc.	Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
TWI255718B (en)	1999-07-02	2006-06-01	Chugai Pharmaceutical Co Ltd	Ameliorative agent for low vasopressin concentration
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP1238985B1 (en) *	1999-09-30	2008-03-05	Kyowa Hakko Kogyo Co., Ltd.	Human type complementarity determining region transplantation antibody against ganglioside gd3 and derivatives of antibody against ganglioside gd3
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
PT1234031T (pt)	1999-11-30	2017-06-26	Mayo Foundation	B7-h1, uma nova molécula imunoregulatória
DE60043308D1 (de)	1999-12-16	2009-12-24	Biogen Idec Inc	Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
US6656467B2 (en)	2000-01-27	2003-12-02	Medimmune, Inc.	Ultra high affinity neutralizing antibodies
ES2293973T3 (es) *	2000-02-03	2008-04-01	Millennium Pharm Inc	Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
CA2399387C (en)	2000-02-11	2015-11-03	Biogen, Inc.	Heterologous polypeptide of the tnf family
KR100767146B1 (ko)	2000-02-24	2007-10-15	워싱톤 유니버시티	Ａβ 펩티드를 격리시키는 인간화 항체
EP2341074A1 (en)	2000-03-01	2011-07-06	MedImmune, LLC	Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
US6663863B2 (en)	2000-03-17	2003-12-16	Millennium Pharmaceuticals, Inc.	Method of inhibiting stenosis and restenosis
US20010046496A1 (en)	2000-04-14	2001-11-29	Brettman Lee R.	Method of administering an antibody
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
EP1987842A1 (en)	2000-04-28	2008-11-05	Chugai Seiyaku Kabushiki Kaisha	Cell proliferation inhibitor
EP2026073B1 (en)	2000-04-29	2016-03-30	University Of Iowa Research Foundation	Diagnostics and therapeutics for macular degeneration-related disorders
US7279160B2 (en)	2000-05-02	2007-10-09	The Uab Research Foundation	Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en)	2000-05-02	2009-01-13	The Uab Research Foundation	Antibody selective for DR4 and uses thereof
TWI318983B (en)	2000-05-02	2010-01-01	Uab Research Foundation	An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
GB0013810D0 (en)	2000-06-06	2000-07-26	Celltech Chiroscience Ltd	Biological products
GB0020685D0 (en)	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
WO2002028481A2 (en)	2000-10-02	2002-04-11	Chiron Corporation	Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US7459287B2 (en)	2004-01-30	2008-12-02	Dana Farber Cancer Institute, Inc.	Method for determination and quantification of radiation or genotoxin exposure
US6989247B2 (en)	2000-11-28	2006-01-24	Celltech R & D, Inc.	Compositions and methods for diagnosing or treating psoriasis
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en)	2000-11-28	2007-02-20	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
BR0208656A (pt)	2001-04-06	2004-08-10	Univ Bristol	Uso de moléculas ligantes de cd25 em pacientes resistentes a esteróides
UA83791C2 (ru)	2001-04-13	2008-08-26	Байоджен Айдек Ма Инк.	Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
US6972324B2 (en)	2001-05-18	2005-12-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Antibodies specific for CD44v6
BR0210905A (pt) *	2001-05-18	2004-06-08	Boehringer Ingelheim Int	Anticorpos especìficos para cd44v6
US7541443B2 (en) *	2001-06-14	2009-06-02	Tolerrx, Inc.	Anti-CD4 antibodies
IL159177A0 (en)	2001-06-20	2004-06-01	Prochon Biotech Ltd	Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030013081A1 (en)	2001-06-26	2003-01-16	Olson William C.	Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
JP4675512B2 (ja) *	2001-07-10	2011-04-27	三井化学株式会社	熱殺菌方法
WO2003062370A2 (en)	2001-07-19	2003-07-31	Perlan Therapeutics, Inc.	Multimeric proteins and methods of making and using same
DE60226036T9 (de)	2001-08-03	2016-09-29	Medical & Biological Laboratories Co., Ltd.	ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
ES2391905T3 (es)	2001-08-17	2012-11-30	Washington University	Método de ensayo para la enfermedad de alzheimer
PT1434871T (pt)	2001-09-20	2017-04-05	Immunex Corp	Seleção de células que expressam polipéptidos heteroméricos
NZ531818A (en)	2001-09-25	2005-10-28	Fujisawa Pharmaceutical Co	Recombinant anti-osteopontin antibody and use in the treatment of autoimmune diseases such as rheumatoid arthritis and osteoarthritis
GB0124317D0 (en)	2001-10-10	2001-11-28	Celltech R&D Ltd	Biological products
US20030190705A1 (en) *	2001-10-29	2003-10-09	Sunol Molecular Corporation	Method of humanizing immune system molecules
WO2003042247A2 (en) *	2001-11-12	2003-05-22	Merck Patent Gmbh	Modified anti-tnf alpha antibody
EP1944043A1 (en)	2001-11-21	2008-07-16	The Trustees of the University of Pennsylvania	Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
KR100987360B1 (ko)	2001-11-21	2010-10-12	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법
EP1461300B1 (en)	2001-11-30	2011-07-27	Biogen Idec MA Inc.	Antibodies against monocyte chemotactic proteins
ES2384100T3 (es) *	2001-12-03	2012-06-29	Alexion Pharmaceuticals, Inc.	Método para producir anticuerpos híbridos
US7393648B2 (en)	2001-12-03	2008-07-01	Alexion Pharmaceuticals, Inc.	Hybrid antibodies
GB0129105D0 (en)	2001-12-05	2002-01-23	Celltech R&D Ltd	Expression control using variable intergenic sequences
CN100522999C (zh) *	2002-02-14	2009-08-05	免疫医疗公司	抗cd20抗体及其融合蛋白和使用方法
ATE414142T1 (de) *	2002-02-22	2008-11-15	Progenics Pharm Inc	Anti-ccr5 antikörper
PL215263B1 (pl)	2002-02-25	2013-11-29	Elan Pharm Inc	Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
EP2336185A1 (en)	2002-03-13	2011-06-22	Biogen Idec Inc.	Anti- alpha v beta 6 antibodies
ATE500273T1 (de)	2002-03-20	2011-03-15	Ucb Pharma Sa	Methoden zur analyse von antikörperdisulfidisomere
WO2003080675A2 (en)	2002-03-22	2003-10-02	Amrad Operations Pty Ltd	MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1)
GB0210121D0 (en)	2002-05-02	2002-06-12	Celltech R&D Ltd	Biological products
EP1507866B1 (en)	2002-05-14	2010-07-07	Martek Biosciences Corporation	Carotene synthase gene and uses therefor
AU2003240790A1 (en)	2002-05-28	2003-12-12	Pharmacia Corporation	Antibody peg positional isomers, compositions comprising same, and use thereof
JP4524181B2 (ja) *	2002-05-30	2010-08-11	マクロジェニクス，インコーポレーテッド	Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
ATE415416T1 (de)	2002-06-14	2008-12-15	Monier Tadros	Methode für die herstellung von protamin
GB0213745D0 (en)	2002-06-14	2002-07-24	Univ Edinburgh	Enzyme
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
JP2005535636A (ja) *	2002-06-28	2005-11-24	アメリカ合衆国	インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
US9535076B2 (en)	2002-09-12	2017-01-03	The Regents Of The University Of California	Methods and compositions for eliciting an amyloid-selective immune response
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
GB0228832D0 (en)	2002-12-10	2003-01-15	Novartis Ag	Organic compound
US8506959B2 (en)	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en)	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
EA013677B1 (ru)	2002-11-15	2010-06-30	Генмаб А/С	Человеческие моноклональные антитела против cd25 и их применение
CA2537263C (en)	2002-11-27	2017-05-30	Minerva Biotechnologies Corporation	Techniques and compositions for the diagnosis and treatment of cancer (muc1)
PT1572744E (pt)	2002-12-16	2010-09-07	Genentech Inc	Variantes de imunoglobulina e utilizações destas
AU2004205684A1 (en)	2003-01-23	2004-08-05	Genentech, Inc.	Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
KR20050114212A (ko)	2003-01-24	2005-12-05	엘란 파마슈티칼스, 인크.	수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료및 조성물
EP1460088A1 (en) *	2003-03-21	2004-09-22	Biotest AG	Humanized anti-CD4 antibody with immunosuppressive properties
US7321065B2 (en)	2003-04-18	2008-01-22	The Regents Of The University Of California	Thyronamine derivatives and analogs and methods of use thereof
MXPA05011406A (es)	2003-04-23	2005-12-12	Medarex Inc	Anticuerpos humanizados para el receptor-1 de interferon alfa (ifnar-1).
EP1631312B1 (en)	2003-04-23	2008-09-10	Medarex, Inc.	Compositions and methods for the therapy of inflammatory bowel disease
DK1633189T3 (en)	2003-05-19	2017-08-21	Prothena Biosciences Ltd	TRUNCTED FRAGMENTS OF ALFA SYNUCLEIN IN LEWY BODY DISEASE
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
JP4667383B2 (ja)	2003-06-13	2011-04-13	バイオジェン・アイデック・エムエイ・インコーポレイテッド	アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
US8153410B2 (en)	2003-07-07	2012-04-10	Fox Chase Cancer Center	Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20060162014A1 (en)	2003-07-07	2006-07-20	Jaffe Eileen K	Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
EP1641822B1 (en)	2003-07-08	2013-05-15	Genentech, Inc.	Il-17 a/f heterologous polypeptides and therapeutic uses thereof
RS53476B (sr)	2003-07-18	2014-12-31	Amgen Fremont Inc.	Sredstva za specifično vezivanje faktora rasta hepatocita
US7834155B2 (en)	2003-07-21	2010-11-16	Immunogen Inc.	CA6 antigen-specific cytotoxic conjugate and methods of using the same
US20060228350A1 (en) *	2003-08-18	2006-10-12	Medimmune, Inc.	Framework-shuffling of antibodies
GB0321997D0 (en)	2003-09-19	2003-10-22	Novartis Ag	Organic compound
EP1693385A4 (en)	2003-11-11	2009-11-04	Chugai Pharmaceutical Co Ltd	ANTI-CD47 ANTIBODIES HUMANIZED
AU2004290059A1 (en)	2003-11-12	2005-05-26	Albert Einstein College Of Medicine Of Yeshiva University	Novel sequences encoding hepatitis C virus glycoproteins
ES2324538T3 (es)	2003-12-05	2009-08-10	Multimmune Gmbh	Anticuerpos anti-hsp terapeuticos y de diagnostico.
WO2005056599A2 (en)	2003-12-08	2005-06-23	Morphotek, Inc.	Antibodies that specifically bind pms2
EP1699487A4 (en)	2003-12-15	2009-07-08	Alexion Pharma Inc	NEW ANTI-DC-SIGN ANTIBODIES
ITRM20030601A1 (it) *	2003-12-24	2005-06-25	Lay Line Genomics Spa	Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
EP3476861A1 (en)	2004-01-07	2019-05-01	Novartis Vaccines and Diagnostics, Inc.	M-csf-specific monoclonal antibody and uses thereof
JPWO2005068504A1 (ja)	2004-01-19	2008-01-10	株式会社医学生物学研究所	炎症性サイトカイン抑制剤
EP1713503B1 (en)	2004-02-10	2013-07-31	The Regents of the University of Colorado, a Body Corporate	Inhibition of factor b, the alternative complement pathway and methods related thereto
AU2005214331B2 (en)	2004-02-12	2011-09-15	Eisai, Inc.	Monoclonal antibodies that specifically bind to folate receptor alpha
TWI359026B (en)	2004-02-12	2012-03-01	Sankyo Co	Pharmaceutical composition for the osteoclast rela
JP4824547B2 (ja)	2004-02-20	2011-11-30	インテレクトニュウロサイエンシス，インク．	モノクローナル抗体およびその利用
AU2005224081B2 (en)	2004-03-12	2011-06-30	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7625549B2 (en)	2004-03-19	2009-12-01	Amgen Fremont Inc.	Determining the risk of human anti-human antibodies in transgenic mice
WO2005092926A2 (en)	2004-03-19	2005-10-06	Amgen Inc.	Reducing the risk of human and anti-human antibodies through v gene manipulation
CA2561686C (en)	2004-03-31	2014-12-02	Genentech, Inc.	Humanized anti-tgf-beta antibodies
MY162179A (en)	2004-04-01	2017-05-31	Elan Pharm Inc	Steroid sparing agents and methods of using same
HRP20130782T1 (en)	2004-04-02	2013-09-30	The Regents Of The University Of California, Office Of Technology Transfer	Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
EP1761784B1 (en)	2004-05-24	2016-10-26	Universität Zu Köln	Identification of ergothioneine transporter and therapeutic uses thereof
EP1602926A1 (en)	2004-06-04	2005-12-07	University of Geneva	Novel means and methods for the treatment of hearing loss and phantom hearing
EP1781705B1 (en)	2004-06-21	2014-10-08	Medarex, L.L.C.	Interferon alpha receptor i antibodies and their uses
GB0414054D0 (en)	2004-06-23	2004-07-28	Owen Mumford Ltd	Improvements relating to automatic injection devices
EA014226B1 (ru)	2004-07-26	2010-10-29	Байоджен Айдек Ма Инк.	Антитела к cd154, их фрагменты и способы применения антител и фрагментов
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
EA013752B1 (ru)	2004-08-09	2010-06-30	Элан Фармасьютикалз, Инк.	Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
CA2478458A1 (en)	2004-08-20	2006-02-20	Michael Panzara	Treatment of pediatric multiple sclerosis
FI20041204A0 (fi)	2004-09-16	2004-09-16	Riikka Lund	Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
US7910100B2 (en)	2004-10-01	2011-03-22	Max-Planck-Gesellschaft zur Forderung der Wissen	Antibodies directed to the mammalian EAG1 ion channel protein
PT3428191T (pt)	2004-10-06	2024-12-30	Mayo Found Medical Education & Res	B7-h1 e tratamento do carcinona de células renais
WO2006047340A2 (en)	2004-10-22	2006-05-04	Amgen Inc.	Methods for refolding of recombinant antibodies
WO2006055178A2 (en)	2004-10-25	2006-05-26	Merck & Co., Inc.	Anti-addl antibodies and uses thereof
JP2008520717A (ja)	2004-11-19	2008-06-19	バイオジェン・アイデック・エムエイ・インコーポレイテッド	多発性硬化症についての処置
AR052051A1 (es)	2004-12-15	2007-02-28	Neuralab Ltd	Anticuerpos ab humanizados usados en mejorar la cognicion
AU2006204459B2 (en)	2005-01-05	2012-11-01	F-Star Therapeutics Limited	Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
DK2682126T3 (en)	2005-01-27	2017-02-27	Children's Hospital & Res Center At Oakland	GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
EP2357257B1 (en)	2005-02-14	2019-07-31	University of Iowa Research Foundation	Methods and reagents for treatment and diagnosis of age-related macular degeneration
DK2529619T3 (en)	2005-02-17	2016-01-11	Biogen Ma Inc	Treatment of neurological disorders
EP1860119B1 (en)	2005-02-28	2011-08-03	Institute for Antibodies Co., Ltd.	ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME
EP1865985B1 (en)	2005-03-02	2010-08-25	Biogen Idec MA Inc.	Kim-1 antibodies for treatment of th2-mediated conditions
ES2429340T3 (es)	2005-03-10	2013-11-14	Morphotek, Inc.	Anticuerpos anti-mesotelina
WO2006100449A1 (en)	2005-03-19	2006-09-28	Medical Research Council	Improvements in or relating to treatment and prevention of viral infections
ES2657443T3 (es)	2005-03-25	2018-03-05	Gitr, Inc.	Anticuerpos anti-GITR y usos de los mismos
EP2526957A3 (en)	2005-03-30	2013-02-20	Minerva Biotechnologies Corporation	Proliferation of MUC1 expressing cells
DK1875244T3 (en)	2005-03-30	2019-04-29	Minerva Biotechnologies Corp	Proliferation of MUC1-Expressing Cells
KR20140068234A (ko)	2005-03-31	2014-06-05	더 제너럴 하스피탈 코포레이션	Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
DK2645106T4 (da)	2005-04-04	2024-12-02	Biogen Ma Inc	Fremgangsmåder til evaluering af et immunrespons på et terapeutisk middel
AU2006241099B2 (en)	2005-04-22	2012-04-19	Eisai, Inc.	Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
CA2607455A1 (en)	2005-04-22	2006-11-02	Morphotek, Inc.	Antibodies with immune effector activity and that internalize in endosialin-positive cells
WO2006117910A1 (ja)	2005-04-28	2006-11-09	Mochida Pharmaceutical Co., Ltd.	抗血小板膜糖蛋白質ⅵモノクローナル抗体
WO2006117782A2 (en)	2005-05-04	2006-11-09	Quark Pharmaceuticals, Inc.	Recombinant antibodies against cd55 and cd59 and uses thereof
AU2006244068B9 (en)	2005-05-10	2012-10-25	Incyte Holdings Corporation	Modulators of indoleamine 2,3-dioxygenase and methods of using the same
AU2006247188A1 (en)	2005-05-18	2006-11-23	Children's Hospital & Research Center At Oakland	Methods and compositions for immunizing against chlamydia infection
CA2607663C (en)	2005-05-19	2014-08-12	Amgen Inc.	Compositions and methods for increasing the stability of antibodies
ES2548700T3 (es)	2005-05-26	2015-10-20	The Regents Of The University Of Colorado, A Body Corporate	Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
EP2460832A3 (en)	2005-05-27	2012-10-31	Biogen Idec MA Inc.	TWEAK binding antibodies
WO2006138429A2 (en)	2005-06-16	2006-12-28	The Feinstein Institute For Medical Research	Antibodies against hmgb1 and fragments thereof
CA2611519A1 (en)	2005-06-17	2006-12-28	Tolerx, Inc.	Ilt3 binding molecules and uses therefor
CN101228188A (zh) *	2005-06-21	2008-07-23	佐马技术有限公司	IL-1β结合抗体及其片段
CN102875681A (zh)	2005-07-08	2013-01-16	拜奥根Idec马萨诸塞公司	抗-αvβ6抗体及其用途
ES2438019T3 (es)	2005-07-22	2014-01-15	Cytodyn, Inc.	Procedimientos para reducir la carga viral en pacientes infectados por el VIH-1
FR2888850B1 (fr)	2005-07-22	2013-01-11	Pf Medicament	Nouveaux anticorps anti-igf-ir et leurs applications
EP1913027B1 (en)	2005-07-28	2015-03-04	Novartis AG	M-csf specific monoclonal antibody and uses thereof
WO2007030560A2 (en)	2005-09-08	2007-03-15	Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine	Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
CN101313216A (zh)	2005-09-22	2008-11-26	普洛茨股份有限公司	酵母突变体中产生的糖基化多肽及其使用方法
WO2007051077A2 (en)	2005-10-28	2007-05-03	The Regents Of The University Of California	Methods and compounds for lymphoma cell detection and isolation
AU2006307018B2 (en)	2005-10-28	2012-10-25	Meiji Seika Kaisha, Ltd.	Outer coat protein PA5158 of Pseudomonas aeruginosa
ES2431643T3 (es)	2005-11-01	2013-11-27	Abbvie Biotechnology Ltd	Métodos para determinar la eficacia de adalimumab en sujetos que tienen espondilitis anquilosante utilizando CTX-II y MMP3 como biomarcadores
EP1957541A2 (en)	2005-11-21	2008-08-20	Laboratoires Serono SA	Compositions and methods of producing hybrid antigen binding molecules and uses thereof
SG10201706600VA (en)	2005-11-30	2017-09-28	Abbvie Inc	Monoclonal antibodies and uses thereof
DOP2006000277A (es)	2005-12-12	2007-08-31	Bayer Pharmaceuticals Corp	Anticuerpos anti mn y métodos para su utilización
EP1984522B1 (en)	2006-01-18	2010-08-11	The General Hospital Corporation	Methods of increasing lymphatic function
CA2635445A1 (en)	2006-02-22	2007-08-30	University Of Zurich	Methods for treating autoimmune or demyelinating diseases
EP2377887A1 (en)	2006-03-10	2011-10-19	Zymogenetics Inc	Antibodies that bind both IL-17A and IL-17F and methods of using the same
WO2007108152A1 (ja)	2006-03-23	2007-09-27	Tohoku University	高機能性二重特異性抗体
KR20080113239A (ko)	2006-03-30	2008-12-29	메이지 세이카 가부시키가이샤	녹농균의 외막 단백질 ｐａ0427
EP2738178A1 (en)	2006-04-05	2014-06-04	AbbVie Biotechnology Ltd	Antibody purification
CA2564435A1 (en)	2006-04-10	2007-10-10	Abbott Biotechnology Ltd.	Methods for monitoring and treating intestinal disorders
US9624295B2 (en)	2006-04-10	2017-04-18	Abbvie Biotechnology Ltd.	Uses and compositions for treatment of psoriatic arthritis
EP2666479A3 (en)	2006-04-10	2014-03-26	Abbott Biotechnology Ltd	Uses and compositions for treatment of juvenile rheumatoid arthritis
US10119979B2 (en)	2006-05-25	2018-11-06	Biogen Ma Inc.	Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
CN101495632B (zh)	2006-05-31	2011-08-03	安斯泰来制药有限公司	人源化抗人骨桥蛋白抗体
WO2008042024A2 (en)	2006-06-01	2008-04-10	Elan Pharmaceuticals, Inc.	Neuroactive fragments of app
CA2655504A1 (en)	2006-06-15	2007-12-21	Fibron Ltd.	Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
WO2008094176A2 (en)	2006-06-19	2008-08-07	Tolerx, Inc.	Ilt3 binding molecules and uses therefor
KR101440795B1 (ko)	2006-06-30	2014-09-22	애브비 바이오테크놀로지 리미티드	자동 주사 장치
AT503889B1 (de)	2006-07-05	2011-12-15	Star Biotechnologische Forschungs Und Entwicklungsges M B H F	Multivalente immunglobuline
EP2292648A3 (en)	2006-07-07	2011-06-08	Intercell AG	Small Streptococcus pyogenes antigens and their use
JP2009542810A (ja)	2006-07-10	2009-12-03	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Ｓｍａｄ４欠損癌の増殖を阻害するための組成物および方法
EP2975057A1 (en)	2006-07-10	2016-01-20	Fujita Health University	Novel anti-cd73 antibody
US8586716B2 (en)	2006-08-04	2013-11-19	Novartis Ag	EPHB3-specific antibody and uses thereof
JP2010502573A (ja)	2006-08-11	2010-01-28	ユニヴァーシティオブメディスンアンドデンティストリーオブニュージャージー	二重増感剤含有ルミネッセンス化合物および結合体、ならびにその使用
EP3018144A1 (en)	2006-08-18	2016-05-11	XOMA Technology Ltd.	Prlr-specific antibody and uses thereof
EP2500416A1 (en)	2006-09-13	2012-09-19	Abbott Laboratories	Cell culture improvements
EP2500413A1 (en)	2006-09-13	2012-09-19	Abbott Laboratories	Cell culture improvements
JPWO2008032833A1 (ja)	2006-09-14	2010-01-28	株式会社医学生物学研究所	Ａｄｃｃ活性を増強させた抗体及びその製造方法
FR2906533B1 (fr)	2006-09-28	2013-02-22	Pf Medicament	Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
WO2008052796A1 (en)	2006-11-03	2008-05-08	U3 Pharma Gmbh	Fgfr4 antibodies
ES2484842T3 (es)	2006-11-10	2014-08-12	Livtech Inc.	Anticuerpo anti-DLK-1 humana que muestra la actividad antitumoral in vivo
EP2395022A1 (en)	2006-11-17	2011-12-14	Novartis AG	Lingo binding molecules and pharmaceutical use thereof
EP1923069A1 (en)	2006-11-20	2008-05-21	Intercell AG	Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
US8288110B2 (en)	2006-12-04	2012-10-16	Perkinelmer Health Sciences, Inc.	Biomarkers for detecting cancer
KR20140119831A (ko)	2006-12-07	2014-10-10	노파르티스 아게	Ｅｐｈｂ３에 대한 길항제 항체
US8680252B2 (en)	2006-12-10	2014-03-25	Dyadic International (Usa), Inc.	Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
US8440185B2 (en)	2006-12-26	2013-05-14	The Johns Hopkins University	Compositions and methods for the treatment of immunologic disorders
US7989173B2 (en)	2006-12-27	2011-08-02	The Johns Hopkins University	Detection and diagnosis of inflammatory disorders
CA2673659A1 (en)	2006-12-27	2008-07-10	The Johns Hopkins University	Methods of detecting and diagnosing inflamatory responses and disorders by determining the level of soluble b7-h4
JP5694668B2 (ja)	2006-12-29	2015-04-01	ザリージェンツオブザユニバーシティオブコロラド，アボディーコーポレイトＴＨＥＲＥＧＥＮＴＳＯＦＴＨＥＵＮＩＶＥＲＳＩＴＹＯＦＣＯＬＯＲＡＤＯ，ａｂｏｄｙｃｏｒｐｏｒａｔｅ	自己免疫疾患の診断上および治療上の標的ならびにその用途
US8906367B2 (en)	2007-01-05	2014-12-09	University Of Zurich	Method of providing disease-specific binding molecules and targets
EP2269624A3 (en)	2007-01-12	2012-08-08	Intercell AG	Protective proteins of S. agalactiae, combinations thereof and methods of using the same
US8168415B2 (en)	2007-02-07	2012-05-01	The Regents Of The University Of Colorado	Axl fusion proteins as Axl tyrosine kinase inhibitors
HUE031421T2 (hu)	2007-02-16	2017-07-28	Genzyme Corp	Eljárások pajzsmirigy rendellenességek kockázatának azonosítására
PT3067066T (pt)	2007-02-23	2019-06-17	Univ California	Prevenção e tratamento da doença sinucleinopática e amiloidogénica
CN101663047B (zh)	2007-02-23	2014-07-09	纽约哥伦比亚大学理事会	通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径来治疗免疫疾病的方法
DK3067066T3 (da)	2007-02-23	2019-05-20	Prothena Biosciences Ltd	Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
DK2457928T3 (en)	2007-03-13	2017-08-28	Univ Zuerich	Monoclonal human tumor-specific antibody
PL2125894T3 (pl)	2007-03-22	2019-08-30	Biogen Ma Inc.	Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania
WO2008124570A1 (en)	2007-04-05	2008-10-16	Morphotek, Inc.	Methods for inhibiting the binding of endosialin to ligands
WO2008134659A2 (en)	2007-04-27	2008-11-06	Zymogenetics, Inc.	Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2152731A2 (en)	2007-05-02	2010-02-17	Intercell AG	Klebsiella antigens
WO2008143797A1 (en)	2007-05-11	2008-11-27	Genzyme Corporation	Methods of producing a secreted protein
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
US7709215B2 (en)	2007-06-01	2010-05-04	Cytonics Corporation	Method for diagnosing and treating acute joint injury
WO2008154543A2 (en)	2007-06-11	2008-12-18	Abbott Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis
AU2008266051B2 (en)	2007-06-14	2014-07-31	Biogen Ma Inc.	Antibody formulations
EP2511291A3 (en)	2007-06-18	2012-11-07	Intercell AG	Chlamydia antigens
JP5602625B2 (ja)	2007-06-26	2014-10-08	エフ−スタービオテヒノロギッシェフォルシュングス− ウントエントヴィッケルングスゲゼルシャフトミットベシュレンクテルハフツング	結合物質のディスプレイ
KR101560843B1 (ko)	2007-06-27	2015-10-15	고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸	페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
US8591886B2 (en)	2007-07-12	2013-11-26	Gitr, Inc.	Combination therapies employing GITR binding molecules
EP2014681A1 (en)	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2514762B1 (en)	2007-07-13	2015-04-08	The Johns Hopkins University	B7-DC variants
CN110372795A (zh)	2007-08-02	2019-10-25	吉利德生物制剂公司	Lox和loxl2抑制剂及其应用
BRPI0816094A2 (pt)	2007-08-30	2015-03-03	Daiichi Sankyo Co Ltd	Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
EP2186892A1 (en) *	2007-09-06	2010-05-19	Osaka University	Anti-cd20 monoclonal antibodies
WO2009033071A2 (en)	2007-09-07	2009-03-12	Dyadic International, Inc.	Novel fungal enzymes
EP2527369A3 (en)	2007-09-13	2012-12-19	University Of Zurich Prorektorat Forschung	Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2197911A2 (en)	2007-09-14	2010-06-23	Amgen Inc.	Homogeneous antibody populations
HUE025262T2 (en)	2007-10-11	2016-02-29	Daiichi Sankyo Co Ltd	Antibody targeting osteoclast-linked Siglec-15 protein
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
SG185316A1 (en)	2007-10-19	2012-11-29	Immunas Pharma Inc	ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF
CA2704809A1 (en)	2007-11-01	2009-05-07	University Of Iowa Research Foundation	Rca locus analysis to assess susceptibility to amd and mpgnii
ES2425768T3 (es)	2007-11-02	2013-10-17	Novartis Ag	Moléculas de unión a nogo-a mejoradas y uso farmacéutico de las mismas
WO2010008411A1 (en)	2007-11-09	2010-01-21	The Salk Institute For Biological Studies	Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
EP2220121B1 (en)	2007-11-12	2015-08-19	U3 Pharma GmbH	Axl antibodies
CN101883858B (zh)	2007-11-28	2015-07-22	宾夕法尼亚大学托管会	猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
EP2220217A2 (en)	2007-11-28	2010-08-25	The Trustees of the University of Pennsylvania	Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
WO2009079242A2 (en)	2007-12-05	2009-06-25	Massachusetts Institute Of Technology	Aglycosylated immunoglobulin mutants
EP2231181B1 (en)	2007-12-17	2016-02-17	Marfl AB	New vaccine for the treatment of mycobacterium related disorders
US20100291070A1 (en)	2007-12-25	2010-11-18	Meiji Seika Kaisha, Ltd.	Type iii secretion system component protein pa1698 of pseudomonas aeruginosa
AU2008345022B2 (en)	2007-12-28	2014-11-06	Prothena Biosciences Limited	Treatment and prophylaxis of amyloidosis
JP5511684B2 (ja)	2008-01-11	2014-06-04	アドヘロンセラピューティクス，インコーポレイテッド	炎症性関節障害を治療するためのカドヘリン−１１ｅｃｌドメインアンタゴニスト
PL2243829T3 (pl)	2008-01-11	2015-04-30	Astellas Pharma Inc	Polepszone humanizowane przeciwciało anty-ludzka integryna alfa9,
EP2245156A4 (en) *	2008-01-11	2011-02-02	Gene Techno Science Co Ltd	HUMANIZED ANTI-9 INTEGRIN ANTIBODIES AND USES THEREOF
CA2714413C (en)	2008-02-08	2017-01-24	Immunas Pharma, Inc.	Antibody capable of binding specifically to ab-oligomer, and use thereof
CN102016011B (zh)	2008-03-04	2013-12-11	宾夕法尼亚大学托管会	猿猴腺病毒sadv-36、-42.1、-42.2和-44及其应用
JP5604311B2 (ja)	2008-03-13	2014-10-08	バイオテスト・アクチエンゲゼルシヤフト	疾患治療剤
KR20100135807A (ko)	2008-03-13	2010-12-27	바이오테스트 아게	질병 치료제
CA2718184A1 (en)	2008-03-13	2009-10-08	Biotest Ag	Agent for treating disease
ES2527521T3 (es)	2008-03-17	2015-01-26	Livtech Inc.	Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral
CN101977927A (zh)	2008-03-17	2011-02-16	英特塞尔股份公司	针对肺炎链球菌保护的肽以及与其有关的组合物、方法和用途
AU2009226972B2 (en)	2008-03-17	2014-05-29	Gerhard Heusipp	YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
JPWO2009119794A1 (ja)	2008-03-27	2011-07-28	タカラバイオ株式会社	感染症予防、治療剤
DK2276509T3 (en)	2008-04-11	2016-09-19	Seattle Genetics Inc	DETECTION AND TREATMENT OF CANCER IN PANCREAS, ovarian and other cancers
CN102076865B (zh)	2008-05-02	2016-03-16	西雅图基因公司	用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
EP2113255A1 (en)	2008-05-02	2009-11-04	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Cytotoxic immunoglobulin
JP2011523560A (ja)	2008-06-02	2011-08-18	ダナ−ファーバーキャンサーインスティテュートインク．	Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
US8575314B2 (en)	2008-06-20	2013-11-05	National University Corporation Okayama University	Antibody against oxidized LDL/β2GPI complex and use of the same
SI3628686T1 (sl)	2008-06-25	2022-01-31	Novartis Ag	Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
MX345039B (es)	2008-06-25	2017-01-16	Esbatech Alcon Biomed Res Unit	Anticuerpos estables y solubles que inhiben el tnfa.
KR101834797B1 (ko)	2008-06-25	2018-03-07	에스바테크 - 어 노바티스 컴파니 엘엘씨	보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
SG192485A1 (en)	2008-07-08	2013-08-30	Incyte Corp	1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
US8993728B2 (en)	2008-07-16	2015-03-31	Medical And Biological Laboratories Co., Ltd.	Anti-human CLCP1 antibody and use thereof
RU2492871C2 (ru)	2008-08-01	2013-09-20	АКСИС, Инс.	Терапевтическое или профилактическое средство для лечения остеоартрита
US8795981B2 (en)	2008-08-08	2014-08-05	Molecular Devices, Llc	Cell detection
US8417011B2 (en)	2008-09-18	2013-04-09	Molecular Devices (New Milton) Ltd.	Colony detection
EP2172485A1 (en)	2008-10-01	2010-04-07	Pierre Fabre Medicament	Novel anti CXCR4 antibodies and their use for the treatment of cancer
CA2739076A1 (en)	2008-10-02	2010-04-08	Celtaxsys, Inc.	Methods of modulating the negative chemotaxis of immune cells
KR20140101876A (ko)	2008-10-09	2014-08-20	미네르바 바이오테크놀로지 코포레이션	세포내에서 다능성을 유도하기 위한 방법
DK3199553T3 (da)	2008-10-29	2019-07-22	Circular Commitment Company	Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
DK2350269T3 (en)	2008-10-31	2015-12-07	Univ Pennsylvania	ABE ADENOVIRUS WITH SADV-46 HEXONCAPSIDE PROTEINS AND APPLICATIONS THEREOF
AR074439A1 (es)	2008-12-02	2011-01-19	Pf Medicament	Anticuerpo anti-cmet (receptor c-met)
US9469691B2 (en)	2008-12-02	2016-10-18	Pierre Fabre Medicament	Anti-cMET antibody
US8545839B2 (en)	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody
WO2010069603A1 (en)	2008-12-19	2010-06-24	Neurimmune Therapeutics Ag	Human anti-alpha-synuclein autoantibodies
US8313915B2 (en)	2009-01-21	2012-11-20	Gundersen Lutheran Medical Foundation, Inc.	Early detection of canine lyme disease by specific peptides and antibodies
US20100260752A1 (en)	2009-01-23	2010-10-14	Biosynexus Incorporated	Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
US20130243779A1 (en)	2009-02-05	2013-09-19	Intercell Ag	Peptides protective against e. faecalis, methods and uses relating thereto
US8617574B2 (en)	2009-02-13	2013-12-31	Valneva Austria Gmbh	Nontypable Haemophilus influenzae antigens
US20110306069A1 (en)	2009-02-19	2011-12-15	Qingyu Wu	Corin As A Marker For Heart Failure
JP2012520073A (ja)	2009-03-10	2012-09-06	ベイラーリサーチインスティテュート	抗原提示細胞ターゲティングワクチン
CN105837691B (zh)	2009-03-10	2021-06-29	贝勒研究院	靶向抗原呈递细胞的癌症疫苗
EP2406286B1 (en)	2009-03-10	2016-05-18	Baylor Research Institute	Anti-cd40 antibodies and uses thereof
JP5725508B2 (ja)	2009-03-25	2015-05-27	国立大学法人東北大学	Ｌｈ型二重特異性抗体
CN106317224B (zh)	2009-04-09	2020-05-12	第一三共株式会社	抗-Siglec-15抗体
EP2990051B1 (en)	2009-04-10	2016-10-26	Tufts Medical Center, Inc.	Par-1 activation by metalloproteinase-1 (mmp-1)
JP5812418B2 (ja)	2009-04-17	2015-11-11	イムナス・ファーマ株式会社	Ａβオリゴマーに特異的に結合する抗体およびその利用
US8636704B2 (en)	2009-04-29	2014-01-28	Abbvie Biotechnology Ltd	Automatic injection device
EP2246364A1 (en)	2009-04-29	2010-11-03	Pierre Fabre Médicament	Anti CXCR4 antibodies for the treatment of HIV
EP2270053A1 (en)	2009-05-11	2011-01-05	U3 Pharma GmbH	Humanized AXL antibodies
CA2762203A1 (en)	2009-05-29	2010-12-02	Soumitra Roy	Simian adenovirus 41 and uses thereof
EP2260864A1 (en)	2009-06-10	2010-12-15	University of Melbourne	Therapeutic applications
TWI513465B (zh)	2009-06-25	2015-12-21	Regeneron Pharma	以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
EP2456460A4 (en)	2009-07-24	2013-02-20	Univ California	METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN
CA2768330A1 (en)	2009-07-28	2011-02-03	F. Hoffmann-La Roche Ag	Non-invasive in vivo optical imaging method
WO2011015379A1 (en)	2009-08-05	2011-02-10	Nexigen Gbmh	Human hcv-interacting proteins and methods of use
WO2011024114A1 (en)	2009-08-25	2011-03-03	Ecole Polytechnique Federale De Lausanne (Epfl)	Targeting extracellular matrix molecules for the treatment of cancer
TWI412375B (zh)	2009-08-28	2013-10-21	Roche Glycart Ag	人類化抗ｃｄｃｐ１抗體
US9005616B2 (en)	2009-08-31	2015-04-14	Amplimmune, Inc.	Methods and compositions for the inhibition of transplant rejection
JP5913103B2 (ja)	2009-09-14	2016-04-27	ザリージェンツオブザユニバーシティオブコロラド，アボディーコーポレイトＴＨＥＲＥＧＥＮＴＳＯＦＴＨＥＵＮＩＶＥＲＳＩＴＹＯＦＣＯＬＯＲＡＤＯ，ａｂｏｄｙｃｏｒｐｏｒａｔｅ	酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
EP2305285A1 (en)	2009-09-29	2011-04-06	Julius-Maximilians-Universität Würzburg	Means and methods for treating ischemic conditions
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
EP2308897A1 (en)	2009-10-09	2011-04-13	Pierre Fabre Medicament	Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
JP2013507618A (ja)	2009-10-11	2013-03-04	バイオジェン・アイデック・エムエイ・インコーポレイテッド	抗ｖｌａ‐４関連アッセイ
JP5818003B2 (ja)	2009-11-18	2015-11-18	国立大学法人東北大学	ヒト型化抗ｅｇｆｒ抗体可変領域の高機能性変異体
EP2332929A1 (en)	2009-11-25	2011-06-15	ArisGen SA	Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
GB0920944D0 (en)	2009-11-30	2010-01-13	Biotest Ag	Agents for treating disease
US9872905B2 (en)	2009-12-01	2018-01-23	President And Fellows Of Harvard College	Modulation of NK cell antigen specific effector activity by modulation of CXCR6 (CD186)
WO2011075578A1 (en)	2009-12-16	2011-06-23	Philip Bosch	Methods of treating interstitial cystitis
WO2011088193A2 (en)	2010-01-13	2011-07-21	University Of Medicine And Dentistry Of New Jersey	Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency
EP2525822B1 (en)	2010-01-20	2017-05-10	Merck Sharp & Dohme Corp.	Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
CA2787783A1 (en)	2010-01-20	2011-07-28	Tolerx, Inc.	Anti-ilt5 antibodies and ilt5-binding antibody fragments
JP2012246222A (ja)	2010-01-29	2012-12-13	Axis Inc	変形性関節症治療剤または予防剤を製造するための使用
CA2788527A1 (en)	2010-01-29	2011-08-04	Axis Inc.	Pharmaceutical composition for osteoarthritis treatment or prevention and manufacturing method therefor
KR101684246B1 (ko)	2010-01-29	2016-12-08	가부시키가이샤 아크시스	변형성 관절증 치료제를 포함하는 주사제
WO2011097301A2 (en)	2010-02-02	2011-08-11	Abbott Biotechnology Ltd.	METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
UA115517C2 (uk)	2010-02-08	2017-11-27	Ейдженсіс, Інк.	Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b
EP4219560A3 (en)	2010-02-18	2023-08-23	The Regents of The University of California	Integrin alpha v beta 8 neutralizing antibody
EP2544688B1 (en)	2010-03-02	2016-09-07	President and Fellows of Harvard College	Methods and compositions for treatment of angelman syndrome
RU2644335C2 (ru)	2010-03-03	2018-02-08	Зе Юниверсити Оф Бритиш Коламбия	Эпитоп, специфичный к олигомеру амилоида бета, и антитела
US20130041349A1 (en)	2010-03-26	2013-02-14	Westfaelische Wilhelms-Universitaet Muenster	Substitute therapy for glucocorticoids
EP2371863A1 (en)	2010-03-30	2011-10-05	Pierre Fabre Médicament	Humanized anti CXCR4 antibodies for the treatment of cancer
EP3434694B1 (en)	2010-04-09	2020-12-30	Critical Care Diagnostics, Inc.	Soluble human st-2 antibodies and assays
PT2558499T (pt)	2010-04-16	2017-07-14	Biogen Ma Inc	Anticorpos anti-vla-4
CN104906656B (zh)	2010-04-21	2020-01-10	艾伯维生物技术有限公司	用于治疗药剂的受控输送的可佩戴自动注射装置
EP2567234B1 (en)	2010-05-07	2018-09-19	F.Hoffmann-La Roche Ag	Diagnostic method for the detection of cells ex vivo
CA2798778C (en)	2010-05-17	2016-01-05	Livtech, Inc.	Anti-human trop-2 antibody having anti-tumor activity in vivo
WO2011146727A1 (en)	2010-05-19	2011-11-24	Philip Bosch	Methods of treating interstitial cystitis
US9485812B2 (en)	2010-07-08	2016-11-01	Honda Motor Co., Ltd.	High frequency heating coil
JP5934203B2 (ja)	2010-07-14	2016-06-15	メルク・シャープ・エンド・ドーム・コーポレイション	抗ａｄｄｌモノクローナル抗体およびこの使用
BR112013001062A2 (pt)	2010-07-15	2016-05-24	Synovex Corp	anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados
DK2598526T3 (en)	2010-07-29	2018-11-19	Eleven Biotherapeutics Inc	CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS
JP2012034668A (ja)	2010-08-12	2012-02-23	Tohoku Univ	ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
WO2012027494A1 (en)	2010-08-24	2012-03-01	Regents Of The University Of Minnesota	Bispecific targeting reagents
CA2807244A1 (en)	2010-08-27	2012-03-01	University Of Zurich	A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
US9034333B2 (en)	2010-08-27	2015-05-19	University Of Zurich	Method for target and drug validation in inflammatory and/or cardiovascular diseases
WO2012028697A1 (en)	2010-09-01	2012-03-08	Eth Zürich, Institute Of Molecular Biology And Biophysics	Affinity purification system based on donor strand complementation
US20120244141A1 (en)	2010-09-28	2012-09-27	Boehringer Ingelheim International Gmbh	Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
US8497138B2 (en)	2010-09-30	2013-07-30	Genetix Limited	Method for cell selection
US9675693B2 (en)	2010-09-30	2017-06-13	Riken	Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
LT2627672T (lt)	2010-10-11	2018-12-10	Biogen International Neuroscience Gmbh	Žmogaus antikūnai prieš tau baltymą
WO2012051111A2 (en)	2010-10-13	2012-04-19	Janssen Biotech, Inc.	Human oncostatin m antibodies and methods of use
ES2632486T3 (es)	2010-10-18	2017-09-13	Mediapharma S.R.L.	Anticuerpo de unión a ErbB3
AR083495A1 (es)	2010-10-22	2013-02-27	Esbatech Alcon Biomed Res Unit	Anticuerpos estables y solubles
ES3004351T3 (en)	2010-10-22	2025-03-12	Seagen Inc	Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
JP5847188B2 (ja)	2010-10-25	2016-01-20	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	ｓＶＣＡＭおよび／またはｓＭＡｄＣＡＭレベルの差を関連付けることにより、アルファ−４インテグリン活性の差を決定するための方法
KR20140009174A (ko)	2010-10-27	2014-01-22	피에르 파브르 메디카먼트	Hiv의 치료를 위한 항체들
CN103282495B (zh)	2010-10-29	2017-06-09	第一三共株式会社	新的抗dr5抗体
US9072766B2 (en)	2010-11-18	2015-07-07	Beth Israel Deaconess Medical Center, Inc.	Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
AR084141A1 (es)	2010-11-19	2013-04-24	Imai Toshio	Anticuerpos neutralizadores anti-ccl20
EP3075860A1 (en)	2010-11-23	2016-10-05	The Trustees of the University of Pennsylvania	Subfamily e simian adenovirus a1295 and uses thereof
CN103380145B (zh)	2010-12-17	2016-10-12	生物控股有限公司	人类抗-sod1抗体
US9085772B2 (en)	2010-12-27	2015-07-21	National University Corporation Nagoya University	Method for suppressing receptor tyrosine kinase-mediated pro-survival signaling in cancer cell
PL2663580T3 (pl)	2011-01-10	2017-08-31	Ct Atlantic Ltd.	Terapia skojarzona obejmująca przeciwciała wiążące antygen związany z nowotworem
DK2663579T3 (en)	2011-01-14	2017-07-31	Univ California	THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
MY166835A (en)	2011-01-24	2018-07-23	Abbvie Biotechnology Ltd	Automatic injection devices having overmolded gripping surfaces
WO2012104824A1 (en)	2011-02-04	2012-08-09	Ecole polytechnique fédérale de Lausanne (EPFL)	Therapeutic antibodies targeting app-c99
WO2012107589A1 (en)	2011-02-11	2012-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012110843A1 (en)	2011-02-18	2012-08-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
WO2012113775A1 (en)	2011-02-21	2012-08-30	University Of Zurich	Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
JP6385060B2 (ja)	2011-03-07	2018-09-05	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	治療的に活性な抗体のインビボにおける選択
US20140099264A1 (en)	2011-03-07	2014-04-10	F. Hoffman-La Roche Ag	Means and methods for in vivo testing of therapeutic antibodies
WO2012120130A1 (en)	2011-03-09	2012-09-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods to characterize patients suffering from hemolysis
WO2012125680A1 (en)	2011-03-16	2012-09-20	Novartis Ag	Methods of treating vasculitis using an il-17 binding molecule
EP2686417B1 (de)	2011-03-17	2016-06-08	Miltenyi Biotec GmbH	Tcralpha/beta-depletierte zellpräparationen
EP4086338A1 (en)	2011-03-17	2022-11-09	Minerva Biotechnologies Corporation	Method for making pluripotent stem cells
CA2831294A1 (en)	2011-03-25	2012-10-04	Baylor Research Institute	Compositions and methods to immunize against hepatitis c virus
TW201249867A (en)	2011-04-01	2012-12-16	Astellas Pharma Inc	Novel anti-human il-23 receptor antibody
CA2832729A1 (en)	2011-04-21	2012-10-26	Abbvie Inc.	Wearable automatic injection device for controlled administration of therapeutic agents
LT2703486T (lt)	2011-04-25	2018-05-25	Daiichi Sankyo Company, Limited	Anti-b7-h3 antikūnas
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
KR101875155B1 (ko)	2011-05-02	2018-07-09	밀레니엄 파머슈티컬스 인코퍼레이티드	항-α4β7 항체에 대한 제형
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2012154889A1 (en)	2011-05-09	2012-11-15	The Cleveland Clinic Foundation	Serum s100b and uses thereof
WO2012163848A1 (en)	2011-05-27	2012-12-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of crohn's disease
EP2530088A1 (en)	2011-05-30	2012-12-05	Klinikum rechts der Isar der Technischen Universität München	Means and methods for diagnosing and treating multiple sclerosis
JP2014524891A (ja)	2011-06-03	2014-09-25	シーティーアトランティックリミテッド	Ｍａｇｅａ３結合抗体
US20140093514A1 (en)	2011-06-03	2014-04-03	University Of Zurich	Magea3 binding antibodies
EP2718327A1 (en)	2011-06-06	2014-04-16	Neotope Biosciences Limited	Mcam antagonists and methods of treatment
WO2012172449A1 (en)	2011-06-13	2012-12-20	Pfizer Inc.	Lactams as beta secretase inhibitors
US20140120555A1 (en)	2011-06-20	2014-05-01	Pierre Fabre Medicament	Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
LT2723379T (lt)	2011-06-23	2018-10-25	Biogen International Neuroscience Gmbh	Anti-alfa sinukleiną rišančios molekulės
DE202011103324U1 (de)	2011-07-12	2012-01-02	Nekonal S.A.R.L.	Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
GB201112056D0 (en)	2011-07-14	2011-08-31	Univ Leuven Kath	Antibodies
WO2013014262A1 (en)	2011-07-27	2013-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating myhre syndrome
PT2743348T (pt)	2011-08-11	2018-02-23	Astellas Pharma Inc	Novo anticorpo anti-ngf humano
US20140242085A1 (en)	2011-08-12	2014-08-28	Medical & Biological Laboratories Co., Ltd.	Methods and composition for testing, preventing, and treating aspergillus fumigatus infection
EP2741777B1 (en)	2011-08-12	2017-01-18	INSERM - Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical compositions for treatment of pulmonary hypertension
GB201116092D0 (en)	2011-09-16	2011-11-02	Bioceros B V	Antibodies and uses thereof
SMT201800109T1 (it)	2011-09-19	2018-05-02	Axon Neuroscience Se	Terapia a base di proteine e diagnosi di una patologia mediata da tau nella malattia di alzheimer
GB2495115A (en) *	2011-09-29	2013-04-03	Oxford Plastic Sys Ltd	Base for supporting temporary fence panels or posts.
AR088048A1 (es)	2011-10-04	2014-05-07	Univ Columbia	Señuelos notch1 humanos
WO2013050540A1 (en)	2011-10-05	2013-04-11	University Of Bremen	Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
WO2013050441A1 (en)	2011-10-05	2013-04-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
WO2013054320A1 (en)	2011-10-11	2013-04-18	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013055911A1 (en)	2011-10-14	2013-04-18	Dana-Farber Cancer Institute, Inc.	Znf365/zfp365 biomarker predictive of anti-cancer response
WO2013059373A2 (en)	2011-10-17	2013-04-25	Minerva Biotechnologies Corporation	Media for stem cell proliferation and induction
WO2013057313A1 (en)	2011-10-20	2013-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the detection and the treatment of cardiac remodeling
EP2589609A1 (en)	2011-11-03	2013-05-08	Pierre Fabre Medicament	Antigen binding protein and its use as addressing product for the treatment of cancer
US9427464B2 (en)	2011-11-22	2016-08-30	Chiome Bioscience Inc.	Anti-human TROP-2 antibody having an antitumor activity in vivo
US20140328864A1 (en)	2011-11-22	2014-11-06	Inserm (Institut National De La Sente Et De La Recherche Medicale)	Methods and pharmaceutical compositions for reducing airway hyperresponse
US9381229B2 (en)	2011-11-28	2016-07-05	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Pharmaceutical composition for use in the treatment of dysfunction associated with aging
EP2602621A1 (en)	2011-12-08	2013-06-12	Julius-Maximilians-Universität Würzburg	LASP-1, a novel urinary marker for transitional cell carcinoma detection
HK1203372A1 (en) *	2011-12-13	2015-10-30	Nordic Nanovector Asa	Chimeric therapeutic anti - cd37 antibodie hh1
EP2794660A2 (en)	2011-12-23	2014-10-29	Phenoquest AG	Antibodies for the treatment and diagnosis of affective and anxiety disorders
FR2984750B1 (fr)	2011-12-23	2014-01-10	Lfb Biotechnologies	Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
AU2013206788B2 (en)	2011-12-28	2017-11-30	Immunoqure Ag	Method of providing monoclonal auto-antibodies with desired specificity
JP2015509085A (ja)	2012-01-01	2015-03-26	キュービーアイエンタープライゼズリミテッドＱｂｉＥｎｔｅｒｐｒｉｓｅｓＬｔｄ．	治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
EP2812702B1 (en)	2012-02-10	2019-04-17	Seattle Genetics, Inc.	Diagnosis and management of CD30-expressing cancers
NZ629204A (en)	2012-02-16	2016-09-30	Santarus Inc	Anti-vla1 (cd49a) antibody pharmaceutical compositions
US10357566B2 (en)	2012-02-23	2019-07-23	Daiichi Sankyo Europe Gmbh	HER3 inhibitor for modulating radiosensitivity
US9371391B2 (en)	2012-02-28	2016-06-21	Astellas Pharma Inc.	Anti-human IL-23 receptor antibody and encoding polynucleotides
PE20142242A1 (es)	2012-03-15	2015-01-08	Janssen Biotech Inc	Anticuerpos humanos anti-cd27, metodos, y usos
SI2828284T1 (sl)	2012-03-20	2019-10-30	Biogen Ma Inc	Virus JC nevtralizirajoča protitelesa
KR20150003170A (ko)	2012-03-30	2015-01-08	다이이찌 산쿄 가부시키가이샤	ＣＤＲ 개변 항 Ｓｉｇｌｅｃ-15 항체
AU2013241002A1 (en)	2012-03-30	2014-10-09	Daiichi Sankyo Company,Limited	Novel anti-siglec-15 antibody
CN103382223B (zh)	2012-04-01	2015-06-10	上海益杰生物技术有限公司	针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
EP2833900B1 (en)	2012-04-01	2018-09-19	Technion Research & Development Foundation Limited	Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
EP2834641A1 (en)	2012-04-02	2015-02-11	Gundersen Lutheran Health Systems, Inc.	Reagents, methods, and kits for the classification of cancer
CA2870126C (en)	2012-04-09	2020-10-27	Daiichi Sankyo Company, Limited	Anti-fgfr2 antibody
MX356749B (es)	2012-04-27	2018-06-12	Daiichi Sankyo Co Ltd	Anticuerpo anti-homologo 4 de roundabout (robo4).
US9062120B2 (en)	2012-05-02	2015-06-23	Janssen Biotech, Inc.	Binding proteins having tethered light chains
JP6263117B2 (ja)	2012-05-11	2018-01-17	公益財団法人微生物化学研究会	抗ｃｘａｄｒ抗体
MX362497B (es)	2012-05-15	2019-01-21	Eisai Inc	Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
JP6293738B2 (ja)	2012-05-18	2018-03-14	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	亜科ｅサルアデノウイルスａ１３０２、ａ１３２０、ａ１３３１及びａ１３３７ならびにそれらの使用
EP2852679A1 (en)	2012-05-22	2015-04-01	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods for diagnosing and treating focal segmental glomerulosclerosis
EP3508497A1 (en)	2012-05-24	2019-07-10	Mountgate Group Limited	Compositions and methods related to prevention and treatment of rabies infection
ES2778701T3 (es)	2012-07-13	2020-08-11	The Trustees Of The Univ Of Pennsylvania Center For Technology Transfer	Gestión de toxicidad para la actividad antitumoral de CAR
PL2875049T3 (pl)	2012-07-18	2019-07-31	Institut National De La Santé Et De La Recherche Médicale (Inserm)	Sposoby zapobiegania i leczenia przewlekłej choroby nerek (ckd)
KR102165464B1 (ko)	2012-07-19	2020-10-14	레드우드 바이오사이언스 인코포레이티드	Cd22에 대해 특이적인 항체 및 이들의 사용 방법
US9840552B2 (en)	2012-07-30	2017-12-12	National University Corporation Nagoya University	Monoclonal antibody against human midkine
PL3489261T3 (pl)	2012-08-24	2021-08-16	The Regents Of The University Of California	Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
TWI660972B (zh)	2012-09-10	2019-06-01	愛爾蘭商尼歐托普生物科學公司	抗ｍｃａｍ抗體及相關使用方法
JP6282591B2 (ja)	2012-09-13	2018-02-21	中外製薬株式会社	遺伝子ノックイン非ヒト動物
EP2711016A1 (en)	2012-09-21	2014-03-26	Covagen AG	Novel IL-17A binding molecules and medical uses thereof
PL2905335T3 (pl)	2012-10-03	2018-06-29	Chiome Bioscience Inc.	Przeciwciało anty-hdlk-1 wykazujące aktywność przeciwnowotworową in vivo
ES2776029T3 (es)	2012-10-08	2020-07-28	St Jude Childrens Res Hospital	Terapias basadas en el control de la estabilidad y función de las células T reguladoras por medio de un eje neuropilina-1:semaforina
KR102498405B1 (ko)	2012-10-11	2023-02-09	다이이찌 산쿄 가부시키가이샤	글리신아미드 화합물의 제조 방법
DE102012020496A1 (de)	2012-10-18	2014-04-24	Charité - Universitätsmedizin Berlin	Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
WO2014061277A1 (ja)	2012-10-19	2014-04-24	第一三共株式会社	親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
WO2014064203A1 (en)	2012-10-26	2014-05-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
EP2914628A1 (en)	2012-11-01	2015-09-09	Max-Delbrück-Centrum für Molekulare Medizin	An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
CN104955842B (zh)	2012-11-05	2018-04-10	皮埃尔法布雷医药公司	抗原结合蛋白及其作为定位产品用于治疗癌症的用途
EP2917347B1 (en)	2012-11-08	2019-01-02	Institut National de la Sante et de la Recherche Medicale (INSERM)	Methods and pharmaceutical compositions for the treatment of bone metastases
AR093445A1 (es)	2012-11-14	2015-06-10	Regeneron Pharma	Metodos para tratar el cancer de ovario con antagonistas de dll4
ES2780398T3 (es)	2012-12-10	2020-08-25	Biogen Ma Inc	Anticuerpo anti-antígeno 2 de células dendríticas sanguíneas y uso de los mismos
US20160185847A1 (en)	2012-12-17	2016-06-30	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
WO2014100602A1 (en)	2012-12-20	2014-06-26	Hospital For Special Surgery	Treatment of egf-receptor dependent pathologies
JP6284548B2 (ja)	2012-12-21	2018-02-28	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	ヒト抗タウ抗体
WO2014102399A1 (en)	2012-12-31	2014-07-03	Neurimmune Holding Ag	Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
EP2752426A1 (en)	2013-01-03	2014-07-09	Covagen AG	Human serum albumin binding compounds and fusion proteins thereof
MX2015009547A (es)	2013-01-28	2015-11-25	Evec Inc	Anticuerpo anti-hmgb1 humanizado o fragmento de union al antigeno del mismo.
EP2951589A1 (en)	2013-02-01	2015-12-09	INSERM - Institut National de la Santé et de la Recherche Médicale	Methods for predicting and preventing metastasis in triple negative breast cancers
JP6357113B2 (ja)	2013-02-08	2018-07-11	株式会社医学生物学研究所	ヒトｎｒｇ１タンパク質に対する抗体
AU2013378628A1 (en)	2013-02-15	2015-06-11	Esbatech - A Novartis Company Llc	Acceptor framework for CDR grafting
WO2014127811A1 (en)	2013-02-20	2014-08-28	Esbatech - A Novartis Company Llc	Acceptor framework for cdr grafting
FR3004184B1 (fr)	2013-02-26	2016-03-18	Agronomique Inst Nat Rech	Anticorps anti-gluten desamide et utilisations.
ES2673583T3 (es)	2013-02-28	2018-06-22	National Cancer Center	Anticuerpo contra fibrina insoluble
WO2014136910A1 (ja)	2013-03-08	2014-09-12	国立大学法人大阪大学	ペリオスチンのＥｘｏｎ－２１部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物
US10023608B1 (en)	2013-03-13	2018-07-17	Amgen Inc.	Protein purification methods to remove impurities
CA2903706C (en)	2013-03-13	2024-01-23	Eleven Biotherapeutics, Inc.	Chimeric cytokine formulations for ocular delivery
EP2968550B1 (en)	2013-03-14	2018-11-14	Ffe Therapeutics LLC	Compositions and methods for treating angiogenesis-related disorders
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
WO2014143739A2 (en)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Anti-alpha v beta 6 antibodies and uses thereof
US10035859B2 (en)	2013-03-15	2018-07-31	Biogen Ma Inc.	Anti-alpha V beta 6 antibodies and uses thereof
MX2015011670A (es)	2013-03-15	2016-03-31	Biogen Ma Inc	Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
KR20160006168A (ko)	2013-03-18	2016-01-18	바이오서오엑스 프로덕스 비.브이.	인간화 항-cd134(ox40) 항체 및 이의 용도
WO2014165524A2 (en)	2013-04-01	2014-10-09	The Regents Of The University Of California	Methods and compositions for treating and preventing disease associated with avb8 integrin
WO2014174596A1 (ja)	2013-04-23	2014-10-30	株式会社医学生物学研究所	ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
US9717648B2 (en)	2013-04-24	2017-08-01	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN104140974B (zh)	2013-05-08	2017-09-29	科济生物医药（上海）有限公司	编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
CA2952390A1 (en)	2013-06-20	2014-12-24	The Trustees Of The University Of Pennsylvania	Methods for diagnosing pancreatic cancer
EP4056591A1 (en)	2013-07-03	2022-09-14	ImmunoQure AG	Human anti-ifn-alpha antibodies
JP6450381B2 (ja)	2013-07-05	2019-01-09	ユニバーシティオブワシントンスルーイッツセンターフォーコマーシャリゼーション	がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
EP3016973A1 (en)	2013-07-05	2016-05-11	INSERM - Institut National de la Santé et de la Recherche Médicale	Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
HUE043111T2 (hu)	2013-08-09	2019-08-28	Astellas Pharma Inc	Új humán TSLP receptor elleni antitest
WO2015036956A1 (en)	2013-09-12	2015-03-19	Institut National De La Sante Et De La Recherche Medicale	Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
AU2014322988B2 (en)	2013-09-20	2018-12-06	Westfaelische Wilhelms-Universitaet Muenster	Cell-penetrating bacterial E3-ubiqitin-ligases for use in immunotherapy
CA2925087C (en)	2013-09-24	2024-02-13	The Feinstein Institute For Medical Research	Peptides inhibiting cold-inducible rna binding protein activity
EP3049085B9 (en)	2013-09-26	2021-08-18	Beth Israel Deaconess Medical Center, Inc.	Sgk1 inhibitors in the treatment of long qt syndrome
EP3061818B1 (en)	2013-09-30	2020-12-16	Daiichi Sankyo Company, Limited	Anti-lps o11 antibody
US10259875B2 (en)	2013-10-01	2019-04-16	Mayo Foundation For Medical Education And Research	Methods for treating cancer in patients with elevated levels of BIM
ES2768618T3 (es)	2013-10-08	2020-06-23	Daiichi Sankyo Co Ltd	Combinación de anticuerpo anti-FGFR2 y otro agente
LT3065774T (lt)	2013-11-06	2021-09-10	Janssen Biotech, Inc.	Anti-ccl17 antikūnai
JPWO2015068781A1 (ja)	2013-11-06	2017-03-09	国立大学法人大阪大学	インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
WO2015071701A1 (en)	2013-11-15	2015-05-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of pancreatic cancers
WO2015082446A1 (en)	2013-12-02	2015-06-11	F. Hoffmann-La Roche Ag	Treatment of cancer using an anti-cdcp1 antibody and a taxane
RU2016129744A (ru)	2013-12-24	2018-01-30	Астеллас Фарма Инк.	Новое антитело против bdca-2 человека
PT3088419T (pt)	2013-12-25	2019-01-11	Daiichi Sankyo Co Ltd	Conjugado de anticorpo anti-trop2-fármaco
EP3091999B2 (en)	2014-01-09	2025-05-07	Hadasit Medical Research Services and Development Ltd.	Improved cell compositions and methods for cancer therapy
AU2015204503B2 (en)	2014-01-13	2020-07-09	Baylor Research Institute	Novel vaccines against HPV and HPV-related diseases
CN104774264B (zh)	2014-01-15	2018-09-14	上海易乐生物技术有限公司	抗人proBDNF单克隆抗体及其在疼痛中的作用
CA2928794C (en)	2014-01-31	2019-08-13	Daiichi Sankyo Company, Limited	Anti-her2 antibody-drug conjugate
WO2015124570A1 (en)	2014-02-18	2015-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of influenza a virus infection
DK3108255T3 (da)	2014-02-18	2020-11-09	Inst Nat Sante Rech Med	Fremgangsmåder og farmaceutiske sammensætninger til behandling af sygdomme medieret af nrp-1/obr-komplekssignalvejen
EP2915543B1 (en)	2014-03-04	2018-05-09	Albert-Ludwigs-Universität Freiburg	Polypeptides derived from Enterococcus and their use for vaccination and the generation of therapeutic antibodies
WO2015140351A1 (en)	2014-03-21	2015-09-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for enhancing myelination
US20170174764A1 (en)	2014-03-27	2017-06-22	Yeda Research And Development Co. Ltd.	T-cell receptor cdr3 peptides and antibodies
RU2711640C2 (ru)	2014-04-10	2020-01-17	Дайити Санкио Компани, Лимитед	Конъюгат анти-her3 антитело-лекарственное средство
DK3132053T3 (da)	2014-04-15	2020-12-14	Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh	Differentialdiagnose af eksem og psoriasis
US11624093B2 (en)	2014-04-24	2023-04-11	Dana-Farber Cancer Institute, Inc.	Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
JP6835591B2 (ja)	2014-04-25	2021-02-24	ピエール、ファーブル、メディカマン	Ｉｇｆ−１ｒ抗体および癌処置のためのアドレッシングビヒクルとしてのその使用
UA120364C2 (uk)	2014-04-25	2019-11-25	Пьєр Фабр Медікамент	Кон'югат антитіла до igf-1r з лікарським засобом
PL3134125T3 (pl)	2014-04-25	2020-04-30	Pierre Fabre Médicament	Koniugat przeciwciało-lek i jego zastosowanie do leczenia raka
US11427647B2 (en)	2014-04-27	2022-08-30	Famewave Ltd.	Polynucleotides encoding humanized antibodies against CEACAM1
AP2016009504A0 (en)	2014-04-27	2016-10-31	Ccam Biotherapeutics Ltd	Humanized antibodies against ceacam1
WO2015179654A1 (en)	2014-05-22	2015-11-26	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti b7-h1 antibodies
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
EP3598980A3 (en)	2014-06-26	2020-04-15	Yale University	Compositions and methods to regulate renalase in the treatment of diseases and disorders
ES2825708T3 (es)	2014-07-17	2021-05-17	Univ Pennsylvania	Métodos para usar exosomas para monitorizar el estado de órgano trasplantado
CN120137056A (zh)	2014-07-17	2025-06-13	恺兴生命科技(上海)有限公司	靶向cld18a2的t淋巴细胞及其制备方法和应用
US10517875B2 (en)	2014-07-23	2019-12-31	Mayo Foundation for Medical Engineering and Research	Targeting DNA-PKcs and B7-H1 to treat cancer
CN107074937B (zh)	2014-07-29	2021-07-27	神经免疫控股公司	人源抗亨廷顿蛋白(htt)抗体及其用途
NZ729808A (en)	2014-09-30	2022-02-25	Neurimmune Holding Ag	Human-derived anti-dipeptide repeats (dprs) antibody
WO2016054598A2 (en)	2014-10-03	2016-04-07	Massachusetts Institute Of Technology	Antibodies that bind ebola glycoprotein and uses thereof
AU2015328411C1 (en)	2014-10-06	2022-03-03	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016057651A1 (en)	2014-10-09	2016-04-14	Dana-Farber Cancer Institute, Inc.	Multiple-variable il-2 dose regimen for treating immune disorders
EP3220900B1 (en)	2014-11-21	2020-09-23	University of Maryland, Baltimore	Targeted structure-specific particulate delivery systems
US20170319661A1 (en)	2014-12-03	2017-11-09	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers
WO2016128523A1 (en)	2015-02-12	2016-08-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
CA2977532A1 (en)	2015-03-06	2016-09-15	Dana-Farber Cancer Institute, Inc.	Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
EP3067062A1 (en)	2015-03-13	2016-09-14	Ipsen Pharma S.A.S.	Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
US20180092977A1 (en)	2015-03-18	2018-04-05	The Johns Hopkins University	Novel monoclonal antibody inhibitors targeting potassium channel kcnk9
WO2016151018A1 (en)	2015-03-24	2016-09-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method and pharmaceutical composition for use in the treatment of diabetes
US10214591B1 (en)	2015-04-03	2019-02-26	Alienor Farma	Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
EP3283108B1 (en)	2015-04-13	2020-10-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
JP2018519248A (ja)	2015-04-22	2018-07-19	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｔｈ１７媒介性疾患の処置のための方法及び医薬組成物
US10858760B2 (en)	2015-06-01	2020-12-08	Medigene Immunotherapies Gmbh	T cell receptor library
JP2018517711A (ja)	2015-06-01	2018-07-05	メディジーンイミュノテラピーズゲーエムベーハー	細胞表面タンパク質に対する抗体を作製する方法
EA201792662A1 (ru)	2015-06-01	2018-04-30	Медиджин Иммьюнотерапиз Гмбх	Специфические антитела к т-клеточному рецептору
EP3954394A1 (en)	2015-06-19	2022-02-16	Centurion BioPharma Corporation	Delivery systems for controlled drug release
CN108139375A (zh)	2015-06-26	2018-06-08	贝斯以色列女执事医疗中心股份有限公司	靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
CN107922477B (zh)	2015-06-29	2022-11-01	第一三共株式会社	用于选择性制造抗体-药物缀合物的方法
CA2994825A1 (en)	2015-08-05	2017-02-09	Janssen Biotech, Inc.	Anti-cd154 antibodies and methods of using them
JP2018531625A (ja)	2015-09-11	2018-11-01	ナセントバイオテックインコーポレイテッド	脳への向上した薬物送達の方法
WO2017046335A1 (en)	2015-09-18	2017-03-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
EP3353196B1 (en)	2015-09-22	2022-12-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Polypeptides capable of inhibiting the binding between leptin and neuropilin-1
JP6878283B2 (ja)	2015-09-24	2021-05-26	第一三共株式会社	抗ｇａｒｐ抗体
MX2018003905A (es)	2015-09-30	2018-09-06	Janssen Biotech Inc	Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso.
WO2017061615A1 (ja)	2015-10-08	2017-04-13	国立大学法人名古屋大学	キメラ抗原受容体を発現する遺伝子改変ｔ細胞の調製方法
EP3362093A4 (en)	2015-10-13	2019-05-08	Technion Research & Development Foundation Limited	HEPARANASE-NEUTRALIZING MONOCLONAL ANTIBODIES
WO2017064302A1 (en)	2015-10-16	2017-04-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
RU2728568C2 (ru)	2015-10-26	2020-07-30	Пьер Фабр Медикамент	Композиция для лечения рака, экспрессирующего igf-1r
US10875923B2 (en)	2015-10-30	2020-12-29	Mayo Foundation For Medical Education And Research	Antibodies to B7-H1
ITUB20155272A1 (it)	2015-11-02	2017-05-02	Scuola Normale Superiore	Intracellular antibody
SI3370768T1 (sl)	2015-11-03	2022-04-29	Janssen Biotech, Inc.	Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
JP2019503985A (ja)	2015-11-03	2019-02-14	グリコミメティクス，インコーポレイテッド	モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法
ITUB20155097A1 (it)	2015-11-05	2017-05-05	Biouniversa Srl	Anticorpi umanizzati anti-BAG3
WO2017097889A1 (en)	2015-12-10	2017-06-15	Katholieke Universiteit Leuven	Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
EP3390453A2 (en)	2015-12-17	2018-10-24	Janssen Biotech, Inc.	Antibodies specifically binding hla-dr and their uses
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
JP6697562B2 (ja)	2015-12-23	2020-05-20	メディジーンイミュノテラピーズゲーエムベーハー	樹状細胞組成物
EA037032B1 (ru)	2015-12-31	2021-01-28	Прогастрин Э Кансер С.А Р.Л.	Применение и способ для профилактики или лечения рака пищевода с использованием композиции, содержащей прогастрин-связывающее антитело
JP6909795B2 (ja)	2015-12-31	2021-07-28	プロガストリン、エ、カンセル、エス、アーエル、エルＰｒｏｇａｓｔｒｉｎｅＥｔＣａｎｃｅｒｓＳ．ＡＲ．Ｌ．	胃癌の検出および治療のための組成物および方法
US11760808B2 (en)	2015-12-31	2023-09-19	Progastrine Et Cancers S.À R.L.	Compositions and methods for detecting and treating ovarian cancer
EP3202788A1 (en)	2016-02-05	2017-08-09	MediaPharma S.r.l.	Endosialin-binding antibody
WO2017140684A2 (en)	2016-02-15	2017-08-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
EP3205663A1 (en)	2016-02-15	2017-08-16	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Means and methods for inhibiting gene expression
MX2018010445A (es)	2016-03-01	2019-10-17	Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd	Anticuerpos especificos del receptor de poliovirus humano (rvp).
EP3427055A1 (en)	2016-03-07	2019-01-16	Pierre Fabre Medicament	A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
WO2017156263A1 (en)	2016-03-09	2017-09-14	Memorial Sloan-Kettering Cancer Center	Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
WO2017158043A1 (en)	2016-03-15	2017-09-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatement of such disease
WO2017158396A1 (en)	2016-03-16	2017-09-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3433615A1 (en)	2016-03-21	2019-01-30	Institut National de la Sante et de la Recherche Medicale (INSERM)	Methods for diagnosis and treatment of solar lentigo
RU2744959C2 (ru)	2016-03-23	2021-03-17	Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд	Новые анти-pd-l1 антитела
WO2017172596A1 (en)	2016-03-28	2017-10-05	Incyte Corporation	Pyrrolotriazine compounds as tam inhibitors
ITUA20162242A1 (it)	2016-04-01	2017-10-01	St Biochimico Italiano Giovanni Lorenzini Spa	Un nuovo anticorpo anti-erbb2
SI3445785T1 (sl)	2016-04-18	2022-11-30	Faron Pharmaceuticals Oy,	Humanizirana protitelesa proti CLEVER-1 in njihova uporaba
WO2017191100A1 (en)	2016-05-03	2017-11-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of tissue lesions
BR112018073316A2 (pt)	2016-05-11	2019-06-04	Amgen Inc	seleção direta de células que expressam altos níveis de proteínas heteroméricas usando vetores de complementação intragênica da glutamina sintetase
EP3458093A1 (de)	2016-05-20	2019-03-27	Christoph Karl	Pharmazeutische zusammensetzungen mit anti-rankl-antikörpern, kalzium und vitamin d, geeignet zur behandlung und/oder prophylaxe von erkrankungen des knochenstoffwechsels und von therapiebedingten nebenwirkungen wie hypokalzämien
EP3464357A1 (en)	2016-05-24	2019-04-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
WO2017202814A1 (en)	2016-05-24	2017-11-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
US12048718B2 (en)	2016-06-07	2024-07-30	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft	Chimeric antigen receptor and CAR-T cells that bind BCMA
GB201610198D0 (en)	2016-06-10	2016-07-27	Ucb Biopharma Sprl	Anti-ige antibodies
ES2883182T3 (es)	2016-07-06	2021-12-07	Prothena Biosciences Ltd	Ensayo para la detección de alfa-sinucleína total y fosforilada en S129
JP2018035137A (ja)	2016-07-13	2018-03-08	マブイミューンダイアグノスティックスエイジーＭａｂｉｍｍｕｎｅＤｉａｇｎｏｓｔｉｃｓＡｇ	新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
MA45715A (fr)	2016-07-25	2019-05-29	Biogen Ma Inc	Anticorps anti-hspa5 (grp78) et leurs utilisations
JP2019528437A (ja)	2016-07-28	2019-10-10	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	腫瘍関連マクロファージをターゲティングすることによるガン疾患の処置方法
SG11201900744SA (en)	2016-08-12	2019-02-27	Janssen Biotech Inc	Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
CN109863170B (zh)	2016-08-12	2024-08-16	詹森生物科技公司	具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子
US11136409B2 (en)	2016-09-20	2021-10-05	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
WO2018066626A1 (ja)	2016-10-07	2018-04-12	第一三共株式会社	抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療
EP3527225A4 (en)	2016-10-12	2020-06-10	Daiichi Sankyo Company, Limited	COMPOSITION WITH ANTI-ROBO4 ANTIBODIES AND OTHER AGENTS
AU2017343778A1 (en)	2016-10-13	2019-05-02	Massachusetts Institute Of Technology	Antibodies that bind Zika virus envelope protein and uses thereof
IT201600111877A1 (it)	2016-11-07	2018-05-07	Biouniversa Srl	Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
BR112019010064A2 (pt)	2016-11-18	2019-10-01	Astellas Pharma Inc	novo fragmento fab do anticorpo muc1 anti-humano
US11273155B2 (en)	2016-12-12	2022-03-15	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and immune checkpoint inhibitor
EP3556773A4 (en)	2016-12-13	2020-08-19	Astellas Pharma Inc.	HUMAN ANTI-CD73 ANTIBODY
US10836818B2 (en)	2016-12-15	2020-11-17	The National Institute For Biotechnology I	Anti-PCNA monoclonal antibodies and use thereof
EP4606383A3 (en)	2016-12-22	2025-12-17	Daiichi Sankyo Company, Limited	Anti-cd3 antibody and molecules comprising the antibody
US20180179490A1 (en)	2016-12-27	2018-06-28	Miltenyi Biotec Gmbh	CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS
US11773182B2 (en)	2017-01-05	2023-10-03	The Johns Hopkins University	Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
KR102537651B1 (ko)	2017-01-17	2023-05-26	다이이찌 산쿄 가부시키가이샤	항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트
WO2018140510A1 (en)	2017-01-25	2018-08-02	Biogen Ma Inc.	Compositions and methods for treatment of stroke and other cns disorders
SG11201907321TA (en)	2017-02-07	2019-09-27	Daiichi Sankyo Co Ltd	Anti-gprc5d antibody and molecule comprising the antibody
EP3363459A1 (en)	2017-02-17	2018-08-22	Alexander Klimka	Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis
WO2018157169A1 (en)	2017-02-27	2018-08-30	Caerus Therapeutics, Inc.	Antibody constructs and methods of treating cancer
KR20240074000A (ko)	2017-02-28	2024-05-27	다이이찌 산쿄 가부시키가이샤	항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법
CN110753702B (zh)	2017-03-15	2022-09-20	清华大学	抗trkb抗体
JOP20180021A1 (ar)	2017-03-16	2019-01-30	Janssen Biotech Inc	الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2018167283A1 (en)	2017-03-17	2018-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US11879014B2 (en)	2017-03-17	2024-01-23	Tusk Therapeutics Ltd.	Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
ES2904939T3 (es)	2017-03-30	2022-04-06	Progastrine Et Cancers S A R L	Composiciones y métodos para detectar y tratar el cáncer de próstata utilizando una molécula de unión a progastrina
TWI782000B (zh)	2017-03-30	2022-11-01	日商第一三共股份有限公司	抗ｇｐｒ２０抗體、其製造方法及其應用
BR112019020224A2 (pt)	2017-03-30	2020-05-12	Progastrine Et Cancers S.À R.L.	Composições e métodos para o tratamento do câncer de pulmão
US10722589B2 (en)	2017-04-03	2020-07-28	Covagen Ag	FGFR3 binding molecules
WO2018185516A1 (en)	2017-04-05	2018-10-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
EP3610264A1 (en)	2017-04-13	2020-02-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en)	2017-04-14	2018-10-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of cancer
CN111201034A (zh)	2017-05-11	2020-05-26	西托戴恩股份有限公司	涉及施用抗ccr5受体试剂的治疗或预防移植物抗宿主病的方法
TW202530219A (zh)	2017-05-15	2025-08-01	日商第一三共股份有限公司	抗體－藥物結合物之製造方法
MX2019014577A (es)	2017-06-05	2020-07-29	Janssen Biotech Inc	Anticuerpos que se unen especificamente a pd-1 y metodos de uso.
EP3634496A4 (en)	2017-06-06	2021-09-08	Dana-Farber Cancer Institute, Inc.	METHODS FOR SENSITIZING CANCER CELLS TO T-LYMPHOCYTES-MEDIA DESTRUCTION BY MODULATION OF MOLECULAR PATHWAYS
EP3641892A1 (en)	2017-06-23	2020-04-29	Mabylon AG	Anti-allergen antibodies
US20210145828A1 (en)	2017-06-29	2021-05-20	Rutgers, The State University Of New Jersey	Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
US20200115446A1 (en)	2017-06-30	2020-04-16	National University Corporation Hokkaido University	Pediatric osteoporosis drug that does not cause growth disorder
TWI795415B (zh)	2017-07-07	2023-03-11	日商安斯泰來製藥股份有限公司	新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
US11464845B2 (en)	2017-07-21	2022-10-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neisseria meningitidis immunogenic compositions
JP7271424B2 (ja)	2017-07-27	2023-05-11	第一三共株式会社	抗ｃｄ１４７抗体
CA3107625A1 (en)	2017-07-28	2019-01-31	Biouniversa S.R.L.	Anti-bag3 antibodies as therapeutic reagent in cardiovascular diseases
EP3625254B1 (en)	2017-07-31	2023-12-13	F. Hoffmann-La Roche AG	Three-dimensional structure-based humanization method
EP3444272A1 (en)	2017-08-17	2019-02-20	International-Drug-Development-Biotech	Treatment of ck8 positive cancers in relation with k-ras gene status
WO2019038368A1 (en)	2017-08-23	2019-02-28	Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft	CHIMERIC ANTIGEN RECEPTOR AND CAR CXCR5 BINDING T CARRIER
WO2019039483A1 (ja)	2017-08-23	2019-02-28	第一三共株式会社	抗体－薬物コンジュゲートの製剤及びその凍結乾燥方法
WO2019044946A1 (ja)	2017-08-31	2019-03-07	第一三共株式会社	抗体－薬物コンジュゲートの新規製造方法
AU2018327171B2 (en)	2017-08-31	2023-03-09	Daiichi Sankyo Company, Limited	Improved method for producing antibody-drug conjugate
US10610585B2 (en)	2017-09-26	2020-04-07	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and compositions for treating and preventing HIV
CA3077308A1 (en)	2017-09-27	2019-04-04	Incyte Corporation	Salts of pyrrolotriazine derivatives useful as tam inhibitors
IL301638B2 (en)	2017-09-29	2024-09-01	Daiichi Sankyo Co Ltd	Antibody-pyrrolobenzodiazepine derivative conjugate
EP3692997A4 (en)	2017-10-03	2021-09-29	Tokyo Metropolitan Institute of Medical Science	FLU MEDICATION
CN111447952A (zh)	2017-10-05	2020-07-24	第一三共株式会社	用于细胞毒性t细胞耗竭的组合物
KR101966362B1 (ko) *	2017-10-20	2019-04-05	주식회사 녹십자	항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
AU2018364630A1 (en)	2017-11-09	2020-05-21	Pinteon Therapeutics Inc.	Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
EP3717018A1 (en)	2017-11-30	2020-10-07	Centurion BioPharma Corporation	Maytansinoid-based drug delivery systems
AU2018375787B2 (en)	2017-11-30	2023-02-23	Ladrx Corporation	Albumin-binding prodrugs of auristatin E derivatives
WO2019106126A1 (en)	2017-12-01	2019-06-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Mdm2 modulators for the diagnosis and treatment of liposarcoma
PL3720879T3 (pl)	2017-12-05	2022-09-12	Progastrine Et Cancers S.À R.L.	Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu
WO2019121872A1 (en)	2017-12-20	2019-06-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of liver cancer
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2019145537A1 (en)	2018-01-26	2019-08-01	Ecs-Progastrin Sa	Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
WO2019155474A1 (en)	2018-02-12	2019-08-15	Hadasit Medical Research Services & Development Ltd.	Modulation of slamf6 splice variants for cancer therapy
WO2019158512A1 (en)	2018-02-13	2019-08-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the prognosis and the treatment of glioblastoma
KR102699073B1 (ko)	2018-02-27	2024-08-26	이씨에스-프로가스트린 에스에이	면역치료요법용 생체표지자로서 프로가스트린
MA52422A (fr)	2018-02-27	2021-01-06	Incyte Corp	Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b
US20210032334A1 (en)	2018-02-28	2021-02-04	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
TW201946654A (zh)	2018-03-05	2019-12-16	比利時商健生藥品公司	抗ＰＨＦ－Ｔａｕ抗體及其用途
CN111836643A (zh)	2018-03-05	2020-10-27	学校法人埼玉医科大学	用于治疗或预防异位骨化的药物组合物
CN111989344A (zh)	2018-03-09	2020-11-24	科济生物医药（上海）有限公司	用于治疗肿瘤的方法和组合物
US20210047696A1 (en)	2018-03-28	2021-02-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
BR112020015999A2 (pt)	2018-04-06	2020-12-15	Dana-Farber Cancer Institute, Inc.	Kir3dl3 como um receptor de hhla2, anticorpos anti-hhla2 e usos dos mesmos
WO2019197683A1 (en)	2018-04-13	2019-10-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
WO2019201995A1 (en)	2018-04-20	2019-10-24	Medizinische Hochschule Hannover	Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
WO2019207066A1 (en)	2018-04-26	2019-10-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for the treatment of sjögren's syndrome
WO2019211370A1 (en)	2018-05-03	2019-11-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
WO2019211369A1 (en)	2018-05-03	2019-11-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
EP3790900A1 (en)	2018-05-09	2021-03-17	Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.	Antibodies specific to human nectin4
CA3099495A1 (en)	2018-05-11	2019-11-14	Astellas Pharma Inc.	Nucleic acid for treating mite allergy
WO2019216396A1 (ja)	2018-05-11	2019-11-14	アステラス製薬株式会社	甲殻類アレルギー治療のための核酸
BR112020023420A8 (pt)	2018-05-17	2022-07-05	Astellas Pharma Inc	Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
MX2020012376A (es)	2018-05-18	2021-03-09	Incyte Corp	Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
RS66901B1 (sr)	2018-05-24	2025-07-31	Janssen Biotech Inc	Anti-cd3 antitela i njihova upotreba
JOP20200303A1 (ar)	2018-05-24	2020-11-23	Janssen Biotech Inc	عوامل ربط psma واستخداماتها
EA202092849A1 (ru)	2018-05-24	2021-03-16	Янссен Байотек, Инк.	Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
JP7441165B2 (ja)	2018-05-28	2024-02-29	第一三共株式会社	抗ｈｅｒ２抗体－薬物コンジュゲート投与によるｈｅｒ２変異がんの治療
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
JP6790307B2 (ja)	2018-05-31	2020-11-25	第一三共株式会社	抗ヒトｔｌｒ７抗体
TWI848951B (zh)	2018-06-01	2024-07-21	瑞士商諾華公司	針對ｂｃｍａ之結合分子及其用途
US12037398B2 (en)	2018-06-04	2024-07-16	Biogen Ma Inc.	Anti-VLA-4 antibodies having reduced effector function
WO2019234099A1 (en)	2018-06-06	2019-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en)	2018-06-08	2019-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
CA3104467A1 (en)	2018-06-20	2019-12-26	Incyte Corporation	Anti-pd-1 antibodies and uses thereof
US12129298B2 (en)	2018-06-21	2024-10-29	Daiichi Sankyo Company, Limited	Compositions including CD3 antigen binding fragments and uses thereof
PL3813800T3 (pl)	2018-06-29	2025-08-18	Incyte Corporation	Formulacje inhibitora axl/mer
WO2020007898A1 (en)	2018-07-04	2020-01-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating brain injury or neurodegenerative disease
MA53097A (fr)	2018-07-05	2021-05-12	Incyte Corp	Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
TWI865337B (zh)	2018-07-25	2024-12-01	日商第一三共股份有限公司	抗體-藥物結合物之有效的製造方法
TWI846717B (zh)	2018-07-27	2024-07-01	日商第一三共股份有限公司	辨識抗體-藥物結合物之藥物部位的蛋白質
CN112512584A (zh)	2018-07-27	2021-03-16	国立大学法人大阪大学	用于抑制衰老、预防、改善或治疗衰老相关疾病或症状、或者延长寿命的组合物
US12220604B2 (en)	2018-07-31	2025-02-11	Daiichi Sankyo Company, Limited	Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
CA3108754A1 (en)	2018-08-06	2020-02-13	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and tubulin inhibitor
KR102567590B1 (ko)	2018-09-06	2023-08-17	다이이찌 산쿄 가부시키가이샤	신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물 콘쥬게이트
WO2020059772A1 (ja)	2018-09-20	2020-03-26	第一三共株式会社	抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
JP7475687B2 (ja)	2018-09-21	2024-04-30	国立大学法人東京医科歯科大学	ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
BR112021005655A2 (pt)	2018-09-27	2021-06-29	Pierre Fabre Medicament	ligantes à base de sulfomaleimida e conjugados correspondentes
EP3856229A1 (en)	2018-09-28	2021-08-04	Pierre Fabre Medicament	New immunocytokines for the treatment of cancer
EP3865154A4 (en)	2018-10-10	2022-11-09	Astellas Pharma Inc.	PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
EP3867269A1 (en)	2018-10-18	2021-08-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
JP7415939B2 (ja)	2018-10-31	2024-01-17	アステラス製薬株式会社	抗ヒトＦｎ１４抗体
EP3873540A4 (en)	2018-10-31	2022-07-27	Mayo Foundation for Medical Education and Research	METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020092839A1 (en)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
WO2020099235A1 (en)	2018-11-12	2020-05-22	Mediapharma S.R.L.	Bispecific antibodies directed against human 90k and either endosialin or her3
WO2020100954A1 (ja)	2018-11-14	2020-05-22	第一三共株式会社	抗ｃｄｈ６抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
JP7608164B2 (ja)	2018-12-11	2025-01-06	第一三共株式会社	抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ
BR112021011894A2 (pt)	2018-12-21	2021-09-08	Daiichi Sankyo Company, Limited	Composição farmacêutica
KR20210106531A (ko)	2018-12-21	2021-08-30	에임 이뮤노테크 인코포레이티드	암 치료를 위한 조성물 및 방법
CN113301920B (zh)	2019-01-07	2025-01-14	安斯泰来制药株式会社	包含配体、间隔物、肽接头和生物分子的复合物
TWI852977B (zh)	2019-01-10	2024-08-21	美商健生生物科技公司	前列腺新抗原及其用途
EP3908372A1 (en)	2019-01-13	2021-11-17	Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd.	Antibodies specific to human nectin-2
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20220125754A1 (en)	2019-01-29	2022-04-28	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Treating the causative agent in adhesiogenesis
CN113795513B (zh)	2019-02-13	2025-02-18	布里格姆妇女医院	抗外周淋巴结地址素抗体及其用途
WO2020178193A1 (en)	2019-03-01	2020-09-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method of treatment of sarcoidosis
KR20210152472A (ko)	2019-03-11	2021-12-15	메모리얼 슬로안 케터링 캔서 센터	Cd22 항체 및 이를 사용하는 방법
US20220154153A1 (en)	2019-03-22	2022-05-19	Université de Paris	New inhibitors of lrrk2/pp1 interaction
WO2020193628A1 (en)	2019-03-25	2020-10-01	Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft	Enhancement of cytolytic t-cell activity by inhibiting ebag9
JP7627655B2 (ja)	2019-03-25	2025-02-06	第一三共株式会社	抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
WO2020196475A1 (ja)	2019-03-25	2020-10-01	第一三共株式会社	抗ｈｅｒ２抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
CA3139180A1 (en)	2019-03-27	2020-10-01	Daiichi Sankyo Company, Limited	Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
AU2020255907A1 (en)	2019-04-01	2021-10-28	Chiome Bioscience Inc.	Medicament for treating cancer
WO2020206033A1 (en)	2019-04-02	2020-10-08	Kenjockety Biotechnology, Inc.	Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
KR20220002899A (ko)	2019-04-19	2022-01-07	얀센 바이오테크 인코포레이티드	항-psma/cd3 항체로 전립선암을 치료하는 방법
US20220289854A1 (en)	2019-04-30	2022-09-15	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
SG11202111130SA (en)	2019-04-30	2021-11-29	Senti Biosciences Inc	Chimeric receptors and methods of use thereof
US12146160B2 (en)	2019-05-14	2024-11-19	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Regulatory T cells targeted by lymphotoxin alpha blocking agent and uses thereof
CN120098122A (zh)	2019-05-28	2025-06-06	总医院公司	Apoe抗体、融合蛋白及其用途
BR112021023901A2 (pt)	2019-05-29	2022-01-18	Daiichi Sankyo Co Ltd	Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer
CA3144324A1 (en)	2019-06-24	2020-12-30	Novartis Ag	Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
WO2021020282A1 (ja)	2019-07-26	2021-02-04	学校法人埼玉医科大学	Ａｌｋ２／ａｃｖｒ１の細胞外領域を認識する抗体
US12077585B2 (en)	2019-07-26	2024-09-03	Janssen Biotech, Inc.	Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
WO2021019706A1 (ja)	2019-07-31	2021-02-04	国立大学法人信州大学	Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
US20210030869A1 (en)	2019-08-01	2021-02-04	Incyte Corporation	Dosing regimen for an ido inhibitor
EP4007603A1 (en)	2019-08-02	2022-06-08	CytoDyn Inc.	Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
KR20220116575A (ko)	2019-08-12	2022-08-23	비온드 바이오로직스 엘티디	Ilt2에 대한 항체 및 이의 용도
EP3792632A1 (en)	2019-09-16	2021-03-17	Vito NV	Immunotherapy markers
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
US20220348651A1 (en)	2019-09-18	2022-11-03	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
JP2022550067A (ja)	2019-09-27	2022-11-30	ヤンセンバイオテツク，インコーポレーテツド	抗ｃｅａｃａｍ抗体及びその使用
US20220290151A1 (en)	2019-09-27	2022-09-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of müllerian inhibiting substance inhibitors for treating cancer
WO2021079958A1 (ja)	2019-10-25	2021-04-29	第一三共株式会社	抗ｇａｒｐ抗体と免疫調節剤の組み合わせ
AU2020381534A1 (en)	2019-11-15	2022-06-23	Pliant Therapeutics, Inc.	Compositions and methods for activation of integrins
EP4061405A1 (en)	2019-11-18	2022-09-28	Janssen Biotech, Inc.	Vaccines based on mutant calr and jak2 and their uses
PE20221325A1 (es) *	2019-12-10	2022-09-09	Ccoa Therapeutics Inc	Anticuerpos anti-glicoproteina ib alfa humanizada (gpibalpha)
KR20220143005A (ko)	2019-12-20	2022-10-24	노바록 바이오테라퓨틱스 리미티드	항-인터루킨-23 p19 항체 및 이의 사용 방법
CA3166549A1 (en)	2020-01-03	2021-07-08	Incyte Corporation	Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
WO2021140173A1 (en)	2020-01-10	2021-07-15	Biouniversa S.R.L.	Methods and uses for treating fibrotic solid tumors with bags inhibitors
EP4093513A4 (en)	2020-01-24	2024-05-08	Dana-Farber Cancer Institute, Inc.	USE OF BIOMARKERS TO IMPROVE IMMUNOTHERAPY
WO2021156329A1 (en)	2020-02-05	2021-08-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of treatment of cancer disease by targeting an epigenetic factor
IL295515A (en)	2020-02-12	2022-10-01	Janssen Pharmaceutica Nv	Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
AU2021228778A1 (en)	2020-02-28	2022-09-22	The Brigham And Women's Hospital, Inc.	Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
MX2022010327A (es)	2020-03-03	2022-11-09	Active Biotech Ab	Tasquinimod o una sal farmaceuticamente aceptable del mismo para el uso en una terapia combinada.
AU2021230385A1 (en)	2020-03-06	2022-09-22	Incyte Corporation	Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
BR112022015283A2 (pt)	2020-03-06	2022-09-20	Daiichi Sankyo Co Ltd	Conjugado anticorpo-fármaco incluindo derivados de dinucleotídeos cíclicos
JP2023517889A (ja)	2020-03-10	2023-04-27	マサチューセッツインスティテュートオブテクノロジー	ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
UY40280A (es)	2020-03-13	2023-07-31	Janssen Biotech Inc	Dominios de unión a antígeno que se unen a la proteina cd33 de la superficie de células mieloides
US11045546B1 (en)	2020-03-30	2021-06-29	Cytodyn Inc.	Methods of treating coronavirus infection
CA3173263A1 (en)	2020-03-30	2021-10-07	Yasuhiro Matsumura	Antibody drug conjugate
EP3889183A1 (en)	2020-04-01	2021-10-06	Pierre Fabre Medicament	A protein complex comprising an immunocytokine
US20230183342A1 (en)	2020-04-06	2023-06-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
CA3182362A1 (en)	2020-05-14	2021-11-18	Jiangsu Hengrui Medicine Co., Ltd.	Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
EP4153192B8 (en)	2020-05-19	2024-09-04	Institut Curie	Antagonist of cd44/hyaluronic acid pathway for use in a method for the treatment of cytokine release syndrome
KR20230017841A (ko)	2020-05-27	2023-02-06	얀센 바이오테크 인코포레이티드	Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20230029671A (ko)	2020-05-27	2023-03-03	아리아리스 테라퓨틱스, 인크.	항-인간 nr1 항체 유도체
CA3182969A1 (en)	2020-06-04	2021-12-09	Kenjockety Biotechnology, Inc.	Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
WO2021260579A1 (en)	2020-06-24	2021-12-30	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and atr inhibitor
CN116615248A (zh)	2020-06-24	2023-08-18	阿斯利康(英国)有限公司	抗体-药物缀合物和cdk9抑制剂的组合
WO2021260582A1 (en)	2020-06-24	2021-12-30	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and aurora b inhibitor
WO2021260583A1 (en)	2020-06-24	2021-12-30	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and dna-pk inhibitor
JP2023539715A (ja)	2020-06-24	2023-09-19	アストラゼネカユーケーリミテッド	抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
US20230305023A1 (en)	2020-06-25	2023-09-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of treatment and diagnostic of pathological conditions associated with intense stress
EP4175664A2 (en)	2020-07-06	2023-05-10	Janssen Biotech, Inc.	Prostate neoantigens and their uses
WO2022014698A1 (ja)	2020-07-17	2022-01-20	第一三共株式会社	抗体－薬物コンジュゲートの製造方法
CA3186675A1 (en)	2020-07-20	2022-01-27	Yasuki KAMAI	Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor
TW202221028A (zh)	2020-07-29	2022-06-01	美商健生生物科技公司	包括hla-g抗原結合域之蛋白及其用途
RU2764216C1 (ru) *	2020-08-10	2022-01-14	Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова"	Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения
TW202221035A (zh)	2020-08-12	2022-06-01	以色列商拜恩德生物製品有限公司	抗ilt2抗體及其用途
US20230321242A1 (en)	2020-08-24	2023-10-12	Charité - Universitätsmedizin Berlin	Chimeric antigen receptor (car)-expressing cells recognizing cea
AU2021334107A1 (en)	2020-08-24	2023-03-02	Charité - Universitätsmedizin Berlin	A chimeric antigen receptor construct encoding a checkpoint inhibitory molecule and an immune stimulatory cytokine and car-expressing cells recognizing CD44v6
EP4208259A2 (en)	2020-09-04	2023-07-12	NovaRock Biotherapeutics, Ltd.	Nectin-4 antibodies and uses thereof
US20230340149A1 (en)	2020-09-07	2023-10-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of treatment of inflammatory bowel diseases
CN116601713A (zh)	2020-09-12	2023-08-15	阿斯利康(英国)有限公司	用于抗her2抗体-药物缀合物疗法的评分方法
WO2022075482A1 (ja)	2020-10-05	2022-04-14	株式会社カイオム・バイオサイエンス	がん治療用医薬
WO2022074617A1 (en)	2020-10-09	2022-04-14	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and parp1 selective inhibitor
UY39467A (es)	2020-10-13	2022-04-29	Janssen Biotech Inc	Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii
WO2022084399A1 (en)	2020-10-21	2022-04-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	C-terminal sparc fragments for treating cancer
TW202233672A (zh)	2020-10-22	2022-09-01	美商健生生物科技公司	包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
WO2022097090A1 (en)	2020-11-05	2022-05-12	Novartis Ag	Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
US20240011094A1 (en)	2020-11-06	2024-01-11	Institut National de la Santé et de la Recherche Médicale	Methods for diagnosis and treating polycystic ovary syndrome (pcos)
US20230414778A1 (en)	2020-11-11	2023-12-28	Daiichi Sankyo Company, Limited	COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
TW202233249A (zh)	2020-11-12	2022-09-01	日商第一三共股份有限公司	藉由投與抗b7-h3抗體-藥物結合物之間皮瘤之治療
US11897954B2 (en)	2020-11-16	2024-02-13	Astellas Pharma Inc.	Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody
WO2022112469A1 (en)	2020-11-27	2022-06-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosis and monitoring of toxic epidermal necrolysis
WO2022115120A1 (en)	2020-11-30	2022-06-02	Incyte Corporation	Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115762A1 (en)	2020-11-30	2022-06-02	Incyte Corporation	Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022124247A1 (ja)	2020-12-09	2022-06-16	国立大学法人東京医科歯科大学	前頭側頭葉変性症の予防又は治療剤
MX2023007850A (es)	2020-12-29	2023-09-11	Incyte Corp	Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73).
CA3204628A1 (en)	2021-01-13	2022-07-21	John T. POIRIER	Antibody-pyrrolobenzodiazepine derivative conjugate
WO2022153212A1 (en)	2021-01-13	2022-07-21	Axon Neuroscience Se	Antibodies neutralizing sars-cov-2
US20240115721A1 (en)	2021-01-13	2024-04-11	Memorial Sloan Kettering Cancer Center	Anti-dll3 antibody-drug conjugate
AU2022214491A1 (en)	2021-01-28	2023-09-14	Janssen Biotech, Inc.	Psma binding proteins and uses thereof
JP2024505049A (ja)	2021-01-29	2024-02-02	ノバルティスアーゲー	抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
TW202241454A (zh)	2021-02-01	2022-11-01	日商第一三共股份有限公司	抗體－免疫賦活化劑共軛物之新穎製造方法
KR20230159823A (ko)	2021-02-11	2023-11-22	넥틴 테라퓨틱스 리미티드	Cd112r에 대한 항체 및 이의 용도
CA3208905A1 (en)	2021-02-12	2022-08-18	Boehringer Ingelheim International Gmbh	Complement c3 antigen binding proteins
US20220378929A1 (en)	2021-02-25	2022-12-01	MediBoston Limted	Anti-her2 antibody-drug conjugates and uses thereof
CN117425674A (zh)	2021-03-02	2024-01-19	丹娜法伯癌症研究院	治疗红细胞疾患的方法
CN116917341B (zh)	2021-03-12	2025-09-23	第一三共株式会社	糖链以及包含糖链的医药品的制造方法
US20250320308A1 (en)	2021-03-12	2025-10-16	Fibrosys S.R.L.	Monoclonal antibodies for the treatment of viral infections
CN117098781A (zh)	2021-03-24	2023-11-21	詹森生物科技公司	靶向cd22和cd79b的抗体
CA3214307A1 (en)	2021-03-24	2022-09-29	Janssen Biotech, Inc.	Proteins comprising cd3 antigen binding domains and uses thereof
MX2023011340A (es)	2021-03-26	2023-12-14	Janssen Biotech Inc	Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos.
WO2022218998A1 (en)	2021-04-13	2022-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for treating hepatitis b and d virus infection
MX2023012218A (es)	2021-04-14	2023-12-15	Villaris Therapeutics Inc	Anticuerpos anti-cd122 y usos de estos.
CN117222672A (zh)	2021-04-22	2023-12-12	安斯泰来制药株式会社	抗cldn4-抗cd137双特异性抗体
WO2022261183A2 (en)	2021-06-08	2022-12-15	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CN113361141B (zh) *	2021-07-11	2022-02-18	西南石油大学	一种dna图谱算法的改进试验方法
CA3230346A1 (en)	2021-08-27	2023-03-02	Janssen Biotech, Inc.	Anti-psma antibodies and uses thereof
CN118317795A (zh)	2021-09-15	2024-07-09	第一三共株式会社	用在治疗化疗耐药性癌症的方法中的抗体-药物偶联物
US20240316061A1 (en)	2021-09-17	2024-09-26	Institut Curie	Bet inhibitors for treating pab1 deficient cancer
US20250019455A1 (en)	2021-09-24	2025-01-16	Pharmaceutica Nv	Proteins comprising cd20 binding domains, and uses thereof
WO2023052541A1 (en)	2021-09-30	2023-04-06	Imcheck Therapeutics	Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
IL312237A (en)	2021-10-18	2024-06-01	Daiichi Sankyo Co Ltd	Anti-cd37 antibody-drug conjugate
WO2023073084A1 (en)	2021-10-27	2023-05-04	Imcheck Therapeutics	Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
EP4177266A1 (en)	2021-11-05	2023-05-10	Katholieke Universiteit Leuven	Neutralizing anti-sars-cov-2 human antibodies
AU2022392822A1 (en)	2021-11-18	2024-05-02	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and parp1 selective inhibitor
EP4433089A1 (en)	2021-11-19	2024-09-25	Institut Curie	Methods for the treatment of hrd cancer and brca-associated cancer
EP4440594A2 (en)	2021-11-29	2024-10-09	Dana-Farber Cancer Institute, Inc.	Methods and compositions to modulate riok2
WO2023099763A1 (en)	2021-12-03	2023-06-08	Institut Curie	Sirt6 inhibitors for use in treating resistant hrd cancer
JP7235262B1 (ja)	2021-12-07	2023-03-08	国立大学法人大阪大学	抗体又はその抗原結合性断片
WO2023105528A1 (en)	2021-12-12	2023-06-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies specific to ceacam1
AU2022420788A1 (en)	2021-12-22	2024-05-16	Boehringer Ingelheim International Gmbh	Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
TW202334231A (zh)	2021-12-22	2023-09-01	德商莫菲西斯公司	抗cd19抗體療法的治療範例
US20250161305A1 (en)	2021-12-28	2025-05-22	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and rasg12c inhibitor
AU2022429904A1 (en)	2021-12-28	2024-06-06	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and atr inhibitor
AU2023213334A1 (en)	2022-01-27	2024-09-05	Chiome Bioscience Inc.	Anti-human cxcl1 antibody
WO2023152581A1 (en)	2022-02-09	2023-08-17	Janssen Biotech, Inc.	Method of treating cancer with psmaxcd3 antibody
TW202346322A (zh)	2022-03-02	2023-12-01	日商第一三共股份有限公司	含Ｆｃ分子之製造方法
WO2023166081A1 (en)	2022-03-02	2023-09-07	Heidelberg Immunotherapeutics Gmbh	Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
JPWO2023171009A1 (pt)	2022-03-09	2023-09-14
CN118946582A (zh)	2022-03-15	2024-11-12	耶达研究及发展有限公司	抗糖皮质激素诱导的tnfr相关（gitr）蛋白抗体及其用途
KR20240165390A (ko)	2022-03-16	2024-11-22	아스트라제네카 유케이 리미티드	항-trop2 항체-약물 접합체 요법에 대한 점수산정 방법
WO2023210405A1 (ja)	2022-04-25	2023-11-02	公益財団法人東京都医学総合研究所	変異型の神経変性疾患関連タンパク質
TW202400140A (zh)	2022-04-27	2024-01-01	日商第一三共股份有限公司	抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合
JP2025517656A (ja)	2022-05-11	2025-06-10	第一三共株式会社	腫瘍抗原に特異的である抗体と、ｃｄ４７阻害剤との組合せ
TW202413431A (zh)	2022-05-12	2024-04-01	日商安斯泰來製藥股份有限公司	抗ｔａａ和ｃｄ３的多特異性抗體
CN119255825A (zh)	2022-05-24	2025-01-03	第一三共株式会社	抗-cdh6抗体-药物缀合物的剂量方案
EP4537842A1 (en)	2022-06-07	2025-04-16	Institute of Science Tokyo	Preventative agent or therapeutic agent for amyotrophic lateral sclerosis, parkinson's disease, huntington's disease, spinocerebellar ataxia, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging
KR20250049569A (ko)	2022-07-15	2025-04-11	페온 테라퓨틱스 리미티드	항체-약물 접합체
JP2025524992A (ja)	2022-07-28	2025-08-01	アストラゼネカユーケーリミテッド	抗体－薬物コンジュゲートと二重特異性チェックポイント阻害剤との組み合わせ
EP4582106A1 (en)	2022-08-29	2025-07-09	Daiichi Sankyo Company, Limited	Antibody-drug conjugate including mutant fc region
WO2024053574A1 (ja)	2022-09-09	2024-03-14	第一三共株式会社	新規なオリゴ糖、該オリゴ糖の製造中間体、及びそれらの製造方法
WO2024072893A1 (en)	2022-09-28	2024-04-04	Incyte Corporation	Anti-pd-1/lag-3 bispecific antibodies and uses thereof
KR20250080883A (ko)	2022-10-04	2025-06-05	임체크 테라퓨틱스	암 치료에 사용하기 위한 BTN3A 활성화 항체, Bcl-2 억제제 및 저메틸화제의 조합
JP2025535442A (ja)	2022-10-19	2025-10-24	マルチチュード・セラピューティックス・インコーポレーテッド	抗体－薬物コンジュゲート、その調製方法、および、その抗腫瘍への使用
CN120456922A (zh)	2022-11-25	2025-08-08	国立大学法人大阪大学	针对血液癌的抗体
CN120282803A (zh)	2022-11-30	2025-07-08	第一三共株式会社	抗体-药物缀合物和dnmt抑制剂的组合
WO2024121380A1 (en)	2022-12-08	2024-06-13	Pierre Fabre Medicament	Vaccinal composition and adjuvant
CN120958025A (zh)	2022-12-16	2025-11-14	费恩治疗有限公司	针对含cub结构域的蛋白1(cdcp1)的抗体及其用途
KR20250126016A (ko)	2022-12-22	2025-08-22	치오메 바이오사이언스 가부시키가이샤	항인간 cx3cr1 항체
CN120548364A (zh)	2023-01-27	2025-08-26	第一三共株式会社	抗lrrc15抗体
WO2024170505A1 (en)	2023-02-13	2024-08-22	Institut National de la Santé et de la Recherche Médicale	Methods of treatment of iron overload associated diseases
AU2024225483A1 (en)	2023-02-23	2025-08-28	Imcheck Therapeutics	Combination of btn3a activating antibody and immune checkpoint inhibitors
CN120858176A (zh)	2023-03-07	2025-10-28	居里研究所	Brca相关癌症中的ung/udg抑制
WO2024194401A1 (en)	2023-03-21	2024-09-26	Institut Curie	Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194673A1 (en)	2023-03-21	2024-09-26	Institut Curie	Methods for the treatment of dedifferentiated liposarcoma
WO2024194402A1 (en)	2023-03-21	2024-09-26	Institut Curie	Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024213782A1 (en)	2023-04-13	2024-10-17	Institut Curie	Methods for the treatment of t-cell acute lymphoblastic leukemia
TW202442682A (zh)	2023-04-14	2024-11-01	美商英塞特公司	抗ＴＧＦβＲ２／ＰＤ－１雙特異性抗體之用途
TW202506731A (zh)	2023-04-27	2025-02-16	法商感應檢查療法公司	治療多重抗藥性細菌感染之方法
WO2024238787A1 (en)	2023-05-17	2024-11-21	Syndax Pharmaceuticals, Inc.	Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody
WO2025006737A1 (en)	2023-06-30	2025-01-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
WO2025003461A1 (en)	2023-06-30	2025-01-02	Institut National de la Santé et de la Recherche Médicale	Methods of treatment of metabolic disorders
WO2025024272A1 (en)	2023-07-23	2025-01-30	Incyte Corporation	Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody
WO2025034542A1 (en)	2023-08-04	2025-02-13	Cornell University	Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy
US20250136688A1 (en)	2023-08-07	2025-05-01	Janssen Biotech, Inc.	Stabilized cd3 antigen binding agents and methods of use thereof
WO2025040820A1 (en)	2023-08-23	2025-02-27	Granular Therapeutics Limited	Anti-cd203c antibody conjugates and uses thereof
WO2025056739A1 (en)	2023-09-14	2025-03-20	Medizinische Universität Innsbruck	Enhancement of car-t cell efficacy by inhibiting nr2f6
WO2025068180A1 (en)	2023-09-25	2025-04-03	Institut National de la Santé et de la Recherche Médicale	Methods of treatment of cancer by targetting cancer - associated fibroblasts
WO2025068157A1 (en)	2023-09-25	2025-04-03	Stromacare	COMBINATION OF A βIG-H3 ANTAGONIST AND A PDFG-AA ANTAGONIST FOR THE TREATMENT OF CANCER
WO2025068393A1 (en)	2023-09-27	2025-04-03	Institut Curie	Methods for the treatment of fibrotic related diseases
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma
WO2025088496A1 (en)	2023-10-24	2025-05-01	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
EP4563586A1 (en)	2023-11-28	2025-06-04	Université Paris Cité	New inhibitors of lrrk2/pp1 interaction
WO2025120513A1 (en)	2023-12-05	2025-06-12	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
TW202523304A (zh)	2023-12-06	2025-06-16	美商英塞特公司	包含ｄｇｋ抑制劑及ｐｄ—１／ｐｄ—ｌ１抑制劑之組合療法
EP4570262A1 (en)	2023-12-15	2025-06-18	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft	Chimeric antigen receptor directed against the chemokine receptor ccr7
WO2025147576A1 (en)	2024-01-06	2025-07-10	Generate Biomedicines, Inc.	Anti-il-13 antibodies and methods of use thereof
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025176777A1 (en)	2024-02-20	2025-08-28	Institut Curie	Dut inhibition in homologous recombination deficiency cancer
WO2025176860A1 (en)	2024-02-23	2025-08-28	Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts	Dual chimeric antigen receptor construct targeting cea and epcam
FR3159967A1 (fr)	2024-03-06	2025-09-12	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Anticorps neutralisant à haute affinité dirigé contre la ricine
WO2025215252A1 (en)	2024-04-12	2025-10-16	Ensocell Ltd	Therapeutic agents and methods for targeting myeloid cell subtypes
EP4635980A1 (en)	2024-04-19	2025-10-22	Medigene Immunotherapies GmbH	Uni-tags specific antibody
WO2025224050A1 (en)	2024-04-22	2025-10-30	Institut National de la Santé et de la Recherche Médicale	Methods of treatment of patients suffering from hypomelanosis of ito
WO2025226637A1 (en)	2024-04-22	2025-10-30	Incyte Corporation	Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
JPS6033453B2 (ja) *	1978-08-17	1985-08-02	富士電機株式会社	魚切断加工自動化装置
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS6014678A (ja) *	1983-07-04	1985-01-25	Taiheiyo Kogyo Kk	電磁弁
GB8607679D0 (en) *	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB2188941B (en) *	1986-04-14	1990-06-06	Bayer Ag	Monoclonal antibodies recognizing human interleukin-2-receptor
DK554986A (da) *	1986-11-19	1988-07-18	Novo Industri As	Human-human hybride cellelinier samt dermed producerede monoklonale cancerantistoffer
GB8720833D0 (en) *	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
WO1989007452A1 (en) *	1988-02-12	1989-08-24	Medical Research Council	Improvements in or relating to antibodies
EP0362371A4 (en) *	1988-04-15	1990-10-24	Protein Design Labs, Inc.	Il-2 receptor-specific chimeric antibodies
JP5598363B2 (ja)	2011-02-15	2014-10-01	ソニー株式会社	記憶装置およびその動作方法

1989
- 1989-11-27 IL IL162181A patent/IL162181A/en not_active IP Right Cessation
- 1989-12-27 IL IL92904A patent/IL92904A0/xx not_active IP Right Cessation
- 1989-12-28 EP EP98204240.0A patent/EP0939127B1/en not_active Expired - Lifetime
- 1989-12-28 AT AT95105609T patent/ATE183753T1/de not_active IP Right Cessation
- 1989-12-28 EP EP90903576A patent/EP0451216B9/en not_active Expired - Lifetime
- 1989-12-28 DE DE122005000057C patent/DE122005000057I2/de active Active
- 1989-12-28 EP EP10185689A patent/EP2341080A1/en not_active Withdrawn
- 1989-12-28 KR KR1019900701939A patent/KR0178385B1/ko not_active Expired - Lifetime
- 1989-12-28 ES ES04076439.1T patent/ES2523810T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE98204240.0T patent/DE98204240T1/de active Pending
- 1989-12-28 EP EP95105609A patent/EP0682040B1/en not_active Revoked
- 1989-12-28 ES ES04076438.3T patent/ES2440825T3/es not_active Expired - Lifetime
- 1989-12-28 ES ES90903576T patent/ES2081974T5/es not_active Expired - Lifetime
- 1989-12-28 DE DE04076439.1T patent/DE04076439T1/de active Pending
- 1989-12-28 DE DE2000175038 patent/DE10075038I2/de active Active
- 1989-12-28 DE DE04076438.3T patent/DE04076438T1/de active Pending
- 1989-12-28 DE DE122005000007C patent/DE122005000007I2/de active Active
- 1989-12-28 CN CN89109618A patent/CN1057013C/zh not_active Expired - Lifetime
- 1989-12-28 RU SU4895847/13A patent/RU2126046C1/ru active
- 1989-12-28 IE IE20000331A patent/IE20000331A1/en unknown
- 1989-12-28 WO PCT/US1989/005857 patent/WO1990007861A1/en not_active Ceased
- 1989-12-28 PT PT92758A patent/PT92758B/pt active IP Right Grant
- 1989-12-28 AU AU51532/90A patent/AU647383B2/en not_active Expired
- 1989-12-28 DE DE19975047C patent/DE19975047I2/de active Active
- 1989-12-28 AT AT90903576T patent/ATE133452T1/de active
- 1989-12-28 EP EP04076439.1A patent/EP1477497B1/en not_active Expired - Lifetime
- 1989-12-28 DE DE2000175005 patent/DE10075005I2/de active Active
- 1989-12-28 ES ES98204240.0T patent/ES2492815T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE122009000071C patent/DE122009000071I1/de active Pending
- 1989-12-28 EP EP04076438.3A patent/EP1491556B1/en not_active Expired - Lifetime
- 1989-12-28 CA CA002328851A patent/CA2328851C/en not_active Expired - Lifetime
- 1989-12-28 DE DE200712000037 patent/DE122007000037I1/de active Pending
- 1989-12-28 DE DE68925536T patent/DE68925536T3/de not_active Expired - Lifetime
- 1989-12-28 SI SI8912489A patent/SI8912489B/sl unknown
- 1989-12-28 JP JP2503677A patent/JP2828340B2/ja not_active Ceased
- 1989-12-28 ES ES95105609T patent/ES2136760T3/es not_active Expired - Lifetime
- 1989-12-28 CA CA002006865A patent/CA2006865C/en not_active Expired - Lifetime
- 1989-12-28 MC MC@@@@D patent/MC2146A1/xx unknown
- 1989-12-28 YU YU248989A patent/YU48700B/sh unknown
- 1989-12-28 DE DE68929061T patent/DE68929061T2/de not_active Expired - Lifetime
- 1989-12-28 DE DE68925536A patent/DE68925536D1/de not_active Expired - Lifetime
- 1989-12-28 ZA ZA899956A patent/ZA899956B/xx unknown
- 1989-12-28 DE DE1989625536 patent/DE122006000036I1/de active Pending
1990
- 1990-01-04 NZ NZ314793A patent/NZ314793A/xx unknown
- 1990-01-04 NZ NZ231984A patent/NZ231984A/en unknown
- 1990-01-17 DD DD90337159A patent/DD296964A5/de unknown
1991
- 1991-05-20 FI FI912436A patent/FI108797B/fi active Protection Beyond IP Right Term
- 1991-06-19 NO NO19912385A patent/NO310473B1/no not_active IP Right Cessation
- 1991-06-19 DK DK911191A patent/DK119191D0/da not_active Application Discontinuation
- 1991-12-31 CZ CS914186A patent/CZ418691A3/cs unknown
1992
- 1992-01-20 BG BG095784A patent/BG61095B2/xx unknown
- 1992-09-26 HR HRP-2489/89A patent/HRP920500B1/xx not_active IP Right Cessation
1995
- 1995-06-16 HU HU95P/P00236P patent/HU211174A9/hu active Protection Beyond IP Right Term
1996
- 1996-04-13 SG SG1996007855A patent/SG78258A1/en unknown
1998
- 1998-01-12 JP JP00433498A patent/JP3604058B2/ja not_active Expired - Lifetime
- 1998-07-16 DK DK199800941A patent/DK174317B1/da not_active IP Right Cessation
1999
- 1999-07-02 LU LU90411C patent/LU90411I2/fr unknown
- 1999-07-14 NL NL990020C patent/NL990020I2/nl unknown
2000
- 2000-02-11 NL NL300005C patent/NL300005I2/nl unknown
- 2000-02-11 LU LU90528C patent/LU90528I2/fr unknown
- 2000-11-03 NL NL300023C patent/NL300023I2/nl unknown
- 2000-11-09 LU LU90676C patent/LU90676I2/fr unknown
2001
- 2001-12-17 NO NO2001026C patent/NO2001026I2/no unknown
- 2001-12-17 NO NO2001025C patent/NO2001025I2/no unknown
- 2001-12-17 NO NO2001024C patent/NO2001024I1/no unknown
2003
- 2003-01-20 JP JP2003011706A patent/JP2003245091A/ja not_active Withdrawn
- 2003-01-20 JP JP2003011705A patent/JP2003245090A/ja not_active Withdrawn
2005
- 2005-02-04 LU LU91139C patent/LU91139I2/fr unknown
- 2005-02-10 NL NL300173C patent/NL300173I2/nl unknown
- 2005-02-18 NO NO2005005C patent/NO2005005I2/no unknown
- 2005-12-02 LU LU91208C patent/LU91208I2/fr unknown
- 2005-12-07 NO NO2005026C patent/NO2005026I2/no unknown
- 2005-12-12 NL NL300213C patent/NL300213I2/nl unknown
2006
- 2006-08-07 NL NL300239C patent/NL300239I2/nl unknown
- 2006-08-07 LU LU91272C patent/LU91272I2/fr unknown
- 2006-08-07 NO NO2006009C patent/NO2006009I2/no unknown
2007
- 2007-03-02 JP JP2007053539A patent/JP2007145863A/ja not_active Withdrawn
- 2007-04-11 LU LU91333C patent/LU91333I2/fr unknown
- 2007-04-18 NL NL300279C patent/NL300279I2/nl unknown
- 2007-04-18 NO NO2007006C patent/NO2007006I2/no unknown
2009
- 2009-04-21 JP JP2009103471A patent/JP2009165488A/ja not_active Withdrawn
- 2009-11-12 NO NO2009026C patent/NO2009026I1/no unknown
- 2009-11-19 NL NL300426C patent/NL300426I1/nl unknown
- 2009-12-09 LU LU91627C patent/LU91627I2/fr unknown
2014
- 2014-09-17 FR FR14C0070C patent/FR14C0070I1/fr active Active

Also Published As

Publication number	Publication date
RU2126046C1 (ru)	1999-02-10
NO2001026I2 (no)	2006-11-20
CZ418691A3 (en)	1993-10-13
DE68925536T4 (de)	1996-09-19
PT92758B (pt)	1996-01-31
SI8912489A (sl)	1999-02-28
NL990020I2 (nl)	1999-11-01
EP0682040B1 (en)	1999-08-25
HRP920500B1 (en)	1999-12-31
FI912436A0 (fi)	1991-05-20
LU91272I2 (fr)	2006-10-09
LU91208I2 (fr)	2006-02-28
DE68925536D1 (de)	1996-03-07
LU91333I2 (fr)	2007-06-11
SG78258A1 (en)	2001-02-20
DE68925536T2 (de)	1996-06-20
LU90676I2 (fr)	2001-02-05
AU647383B2 (en)	1994-03-24
DE68925536T3 (de)	2012-11-22
JP2003245090A (ja)	2003-09-02
NL300279I2 (nl)	2007-10-01
JPH04502408A (ja)	1992-05-07
ES2440825T3 (es)	2014-05-19
NO912385L (no)	1991-06-19
KR910700350A (ko)	1991-03-14
NO2006009I1 (no)	2006-08-07
DD296964A5 (de)	1991-12-19
ATE133452T1 (de)	1996-02-15
DE19975047I2 (de)	2008-07-03
EP0451216B9 (en)	2012-09-26
YU48700B (sh)	1999-07-28
NL300213I2 (nl)	2006-07-03
LU90411I2 (fr)	1999-09-02
MC2146A1 (fr)	1992-02-18
ZA899956B (en)	1990-10-31
NO310473B1 (no)	2001-07-09
NL300173I1 (nl)	2005-04-01
NL990020I1 (nl)	1999-09-01
JP2009165488A (ja)	2009-07-30
DE04076439T1 (de)	2014-12-18
DK119191A (da)	1991-06-19
NO2005005I2 (no)	2009-01-19
EP0451216A4 (en)	1992-01-02
NZ231984A (en)	1997-06-24
JP3604058B2 (ja)	2004-12-22
DE122005000057I1 (de)	2009-04-09
ES2081974T3 (es)	1996-03-16
EP1477497A1 (en)	2004-11-17
ES2081974T5 (es)	2012-10-29
FI108797B (fi)	2002-03-28
NO2005026I2 (no)	2009-01-19
EP0451216A1 (en)	1991-10-16
KR0178385B1 (ko)	1999-04-01
ES2492815T1 (es)	2014-09-10
IL162181A0 (en)	2005-11-20
DE122009000071I1 (de)	2010-03-25
CA2328851C (en)	2002-08-13
HRP920500A2 (en)	1996-04-30
JP2828340B2 (ja)	1998-11-25
EP0939127A2 (en)	1999-09-01
JPH114694A (ja)	1999-01-12
IL162181A (en)	2006-04-10
DE10075005I1 (de)	2000-11-23
DK199800941A (da)	1998-07-16
ATE183753T1 (de)	1999-09-15
DE10075038I1 (de)	2001-03-01
DE10075038I2 (de)	2004-08-12
EP0451216B2 (en)	2012-06-13
ES2136760T3 (es)	1999-12-01
DE122005000057I2 (de)	2009-07-16
ES2523810T3 (es)	2015-01-12
LU90528I2 (fr)	2000-04-11
CN1043875A (zh)	1990-07-18
NL300239I2 (nl)	2007-03-01
EP1477497B1 (en)	2014-11-26
DE122005000007I1 (de)	2005-06-30
NL300279I1 (nl)	2007-07-02
FR14C0070I1 (fr)	2014-10-24
WO1990007861A1 (en)	1990-07-26
NL300005I2 (nl)	2000-10-02
NO2006009I2 (no)	2009-12-07
ES2492815T3 (es)	2014-10-08
NO2005026I1 (no)	2005-12-27
AU5153290A (en)	1990-08-13
DE04076438T1 (de)	2014-02-27
IE20000331A1 (en)	2001-02-21
CA2006865C (en)	2002-08-20
ES2440825T1 (es)	2014-01-30
EP1491556A1 (en)	2004-12-29
JP2007145863A (ja)	2007-06-14
LU91627I2 (fr)	2010-02-09
EP2341080A1 (en)	2011-07-06
YU248989A (en)	1991-10-31
NL300173I2 (nl)	2006-05-01
EP0939127A3 (en)	2004-07-21
NO2001025I2 (no)	2005-03-21
NO2007006I1 (no)	2007-05-07
LU91139I2 (fr)	2005-04-04
DK174317B1 (da)	2002-12-02
EP0451216B1 (en)	1996-01-24
DE98204240T1 (de)	2014-08-21
NL300023I2 (nl)	2001-09-03
NO2009026I1 (no)	2009-11-30
BG61095B2 (en)	1996-10-31
NL300213I1 (nl)	2006-02-01
CN1057013C (zh)	2000-10-04
NO2001024I1 (no)	2002-01-21
DE122007000037I1 (de)	2007-08-02
DE122005000007I2 (de)	2009-06-25
SI8912489B (sl)	2000-04-30
ES2523810T1 (es)	2014-12-01
EP0939127B1 (en)	2014-09-17
HK1014718A1 (en)	1999-09-30
IL92904A0 (en)	1990-09-17
NO912385D0 (no)	1991-06-19
NZ314793A (en)	1999-11-29
NL300005I1 (nl)	2000-04-03
NL300426I1 (nl)	2010-02-01
NL300239I1 (nl)	2006-10-02
DE122006000036I1 (de)	2007-04-19
DE10075005I2 (de)	2005-06-23
NL300023I1 (nl)	2001-01-02
DK119191D0 (da)	1991-06-19
EP1491556B1 (en)	2014-04-30
NO2007006I2 (no)	2009-12-07
DE68929061D1 (de)	1999-09-30
JP2003245091A (ja)	2003-09-02
HU211174A9 (en)	1995-11-28
CA2328851A1 (en)	1990-06-28
CA2006865A1 (en)	1990-06-28
EP0682040A1 (en)	1995-11-15
DE68929061T2 (de)	2000-04-27

Publication	Publication Date	Title
PT92758A (pt)	1990-06-29	Metodo para conceber uma cadeia de imunoglobulina humanizada

Legal Events

Date	Code	Title	Description
1996-01-31	FG3A	Patent granted, date of granting	Effective date: 19951020
2000-02-29	TE3A	Change of address (patent)	Owner name: PROTEIN DESIGN LABS, INC. Effective date: 19991122
2006-12-29	PD4A	Change of proprietorship	Owner name: PDL BIOPHARMA, INC., US Effective date: 20061106
2008-01-08	TE4A	Change of address (patent)	Owner name: PDL BIOPHARMA, INC., US Effective date: 20071219